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ABSTRACT
Lysyl oxidase (LOX) is the enzyme that catalyzes the formation of aldehydes from 
lysine residues in collagen and elastin resulting in cross-linking. LOX plays a very 
important role in extracellular matrix deposition and maturation. In the context of 
cardiovascular disease, it has been stated that LOX is up-regulated in fibrotic diseases 
suggesting that LOX regulation could contribute to cardiovascular diseases. TNF-a is a 
major pro-inflammatory cytokine that controls some of the pathologies associated 
with the development of atherosclerosis following vascular injury, however, little is 
known about the effect of this cytokine on the regulation of lysyl oxidase in 
cardiovascular tissues.
In addition to lysyl oxidase itself, four other lysyl oxidase related genes have been 
described (LOXL1 -  LOXL4), and these are expressed in vascular tissues. It is of 
interest to determine whether TNF-a regulates lysyl oxidase or its relatives, and 
whether the signal transduction pathways utilized are the same or different. 
Therefore, one of the goals of the current study is to assess for TNF-a regulation of 
lysyl oxidase and its relatives, and to investigate the signal transduction pathways that 
regulate members of this gene family in vitro and in vivo.
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The proteolytic processing of pro-lysyl oxidase results in the formation of the active 
enzyme and a pro-peptide. Important biological activities that are influenced by the 
lysyl oxidase pro-peptide (LOX-PP) include cell proliferation, gene expression and 
signal transduction pathways, specially the MEK/ERK pathway. In this manner, and 
continuing in the context of cardiovascular diseases, our second goal was to 
determine the effect of the LOX-PP in the biological activities of vascular smooth 
muscle cells such as proliferation, migration and signaling pathways.
Initially, immunohistochemistry studies from our lab evaluated the presence in vivo of 
LOX and its isoforms in guidewire-induced femoral artery injury demonstrating LOX 
and LOXL2 elevations when compared to uninjured tissues. To investigate LOX 
isoforms regulation, further, the first part of this project determined the regulation of 
LOX isoforms by TNL-a in primary rat aorta smooth muscle cell cultures.
Data show that TNL-a significantly up-regulates lysyl oxidase enzyme activity. To 
follow mechanisms related to this novel finding, TNL-a regulation of lysyl oxidase and 
LOXL 1- 4 mRNA's were determined, showing a consistent significant stimulatory 
effect mainly on LOXL2 and LOXL4 (2.5-fold) but not LOX itself. To evaluate these 
findings in vivo, 10 week old mice were injected with TNL-a and PBS for 16 hours. 
Mouse aortas were dissected, RNA isolated and qPCR was done. Data shows 
consistent upregulation of LOXL4. Linally, we examined lysyl oxidase protein
expression in media of aorta organ cultures treated with or without TNF-a, and in 
contrast to smooth muscle cell cultures and in vivo studies, our data shows an 
increase of LOX in aortic organ cultures.
For the second part of this project, we determined that LOX-PP inhibits SMC DNA 
synthesis through ERK1/2 and p38 signaling pathways and not JNK. Interestingly, 
TNF-a stimulated cell migration studies showed that LOX-PP inhibits probably by 
inhibiting all three MAP Kinases. Since it is also known that TNF-a strongly up- 
regulates matrix metallproteinases (MMPs), including MMP-9, we wanted to assess 
the effect of the LOX-PP on the TNF-a-regulation of MMP-9. Our findings show that 
LOX-PP is a weak inhibitor of TNF-a stimulated expression of MMP-9, and that the 
ERK1/2 signaling pathway is involved in this process.
This study is the first to suggest that the lysyl oxidase pro-peptide may function to 
control some of the negative effects of the inflammatory cytokine TNF-a, such as 
migration of smooth muscle cells via its ability to inhibit signal transduction pathways
that include ERK1/2 activation.
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1. INTRODUCTION
1.1 Tumor necrosis factor alpha (TNF-a):
TNF-a is a pro-inflammatory cytokine involved in inflammation and is a member of a 
group of cytokines that stimulates the acute phase reaction. It has important effects in 
the pathogenesis of atherosclerosis and is present in the atherosclerotic plaque (Libby, 
P„ 2002; Kleemann, Rv et a/., 2008). TNF-a is mainly produced by macrophages, 
monocytes, and also by some mesenchymal cells including vascular smooth muscle 
cells (VSMC) and fibroblasts (Beutler, B., et a/., 1986; Clausell, N., et a/., 1995; 
Tipping, P.G., et a/., 1993). It has also been reported that endothelial dysfunction can 
be mediated by up-regulation of proinflammatory cytokines like TNF-a, leading to 
the migration of monocytes into the vessel wall intima (Dixon, W.G., et a/., 2007). 
Moreover, TNF-a induces the activation of ERK1/2 via activation of Ras, which is 
critical for the initiation and progression of vascular lesions (Moon, S.K., et a/., 2004).
The biological responses to TNF-a by cells are mediated through signaling pathways. 
The first step is the binding of TNF-a to specific cell surface receptors ubiquitously 
expressed in tissues and cells. Two immunologically distinct receptors have been 
identified: TNFR1 and TNFR2 (Tartaglia, L.A., et a/., 1991). Depending on the tissue
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and the cell type, these receptors can act in regulating different functions. For 
example, TNFR1 can promote cell proliferation and migration or may direct the cell 
into apoptosis due to its capacity to interact with death domain-containing 
intracellular signaling molecules [tumor necrosis factor receptor-1 associated death 
domain protein (TRADD)] to stimulate apoptotic pathways recruiting other factors 
such as receptor interacting protein-1 (RIP1) to stimulate pro- and anti-apoptotic 
pathways. TNFR1 may also be recognized by TNF-receptor associated factors (TRAF1, 
TRAF2 and TRAF6) to stimulate anti-apoptotic pathways (Grivennikov, S.I., ef a/., 
2006). After recognition, these effector proteins mediate the activation of proteases, 
phospholipases, protein kinases and transcription factors (Liu, Z.G., et al., 2001).
Another pathway regulated through TNF-a, and one of the most important pathways 
relevant to our work, is the activation of the Mitogen-Activated Protein Kinase 
(MAPK) signaling pathways. MAPKs are a family of Ser-Thr protein kinases widely 
conserved in eukaryotes that can be activated by different stimuli including 
hormones, growth factors, inflammatory cytokines such as TNF-a, and environmental 
stresses such as osmotic shock. Consequently, a cascade of events involving other 
MAPK kinases lead to different biological processes such as activation of gene 
transcription, protein synthesis, cell proliferation, cell cycle, cell death, cell
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differentiation and movement (Wajant, H., et a/., 2003; Pearson, G., et a/., 2001; 
Kyriakis, J.M., et a/., 2001).
The extracellular signal-regulated kinases (ERK1/2) are proteins of 44 and 42 kDa. 
They are phosphorylated at specific tyrosine and threonine sites which in turn 
activate the kinases. This signaling pathway is activated in response to growth factors, 
cytokines, certain stresses and transforming agents, (Pearson, Gv et a/., 2001). The 
cascade begins when the external stimuli binds to their cell surface receptors and 
cause the activation of the kinase cascade, then Raf phosphorylates and activates the 
dual protein kinases MEK1 and MEK2 which are the activators of ERK1 and ERK2 
(Cobb, M.H., 1999). This pathway finally regulates cell proliferation, and 
differentiation.
The c-Jun N-terminal kinases/Stress activated protein kinases (JNK/SAPK) are 46 and 
54 kDa proteins. They are activated upon phosphorylation of two sites, a tyrosine and 
a threonine. The pathway begins its activation by inflammatory cytokines, certain 
ligands for GPCRs, agents that interfere with DNA and protein synthesis, stresses and 
to some extent by serum, growth factors and transforming agents. Activation pathway 
begins when the stimuli binds to its receptor in the cell membrane, activating MEKK1-
3
4 that in turn activates MKK4 or MKK7 (or the JNK/SAPK Kinases). Then, JNK/SAPK 
translocates into the nucleus where it can regulate the activity of multiple 
transcription factors. The endpoint of this pathway is the regulation of the 
transcription of growth, differentiation, survival and apoptosis (Cobb, M.H., 1999; 
Gallo, K.A., et a/., 2002).
p38 MAPKs (a, (3 and 5) are also activated by a variety of environmental agents such 
as osmotic pressure and heat shock, hormones, GPCRs and inflammatory cytokines. 
As with the other MAPK, the activation pathway begins when a stimulus binds and 
activates a receptor, resulting in MEKK activation, then, phosphorylation and 
activation of MKK3/6 follows and finally p38 MAPK. MKK3/6 can also be activated 
directly by ASK1, which is stimulated by apoptotic stimuli. p38 is translocated into the 
nucleus where it can regulate multiple transcription factors whose endpoints are 
inflammation, apoptosis, growth, differentiation and cytokine production (Pearson, 
G„ et a/., 2001; Gallo, K.A., et a/., 2002).
NF-k B is one of the transcription factors that mediate many TNF-alpha cellular 
responses. In the majority of cases, the activity of NF-k B can be elevated by 
treatment with TNF-a treatment. Inactive NF-k B is sequestered in the cytoplasm 
through interaction with Ik Bs inhibitory proteins. In response to various stimuli
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including TNF-a, Ik Bs are phosphorylated by Ik B kinases (IKKs). Then, activated Ik Bs 
are polyubiquitinated and subsequently degraded by the proteasome. The 
degradation of Ik Bs results in the release of NF-k B and allows its translocation into 
the nucleus and the subsequent activation of its target genes (Liu, Z.G., et a/., 2001).
Figure 1 shows the intracellular signaling pathways downstream of TNF-a.
5
Intracellular signaling pathways downstream of TNF-a.
Figure 1.
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Intracellular signaling pathways downstream of TNF-a.
Figure 1.
The diagram shows some of the intracellular signaling pathways and mediator 
molecules involved in response to TNF-a activation.
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Numerous studies have investigated the effect of TNF-a activation of the MAPKs on 
smooth muscle cells. Goetze, et a/., based on previous studies made on fibroblasts, 
were one of the first who evaluated the effect of TNF-a on vascular smooth muscle 
cell (SMC) migration, identifying the signaling pathways that mediate this process. 
They found that stimulation of rat aortic vascular SMCs with different concentrations 
of TNF-a increased the activation of ERK1/2 using specific antibodies against 
phosphorylated ERK1/2 and total ERK1/2 in Western blot (Goetze, S., et a/., 1999). 
Cho, et a/., studied the signaling pathways involved in the regulation of matrix 
metalloproteinase (MMP)-9 which is a matrix metalloproteinase linked to the 
progression of plaque rupture and intimal formation in arterial lesions. Rat carotid 
arterial smooth muscle cells were treated with TNF-a resulting in a marked increase 
in MMP-9 activity and mRNA levels. TNF-a also caused an increase in JNK, p38 
MAPK and ERK1/2 activities. When cells were treated with pharmacological inhibitors 
for each pathway, up-regulation of MMP-9 expression induced by TNF-a was 
prevented, indicating the involvement of the MAPK pathway on MMP-9 expression in 
vascular smooth muscle cells (Cho, A., et a/., 2000).
Later, other studies had focused on novel treatments to diminish the activation of 
MAPKs by TNF-a on SMC. For example, Rajesh, et a/., treated human coronary artery 
smooth muscle cells (HCASMCs) with TNF-a and they obtained strong activation of
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p38 MAPK, ERK 1/2 and SAPK/JNK demonstrated by Western blot assays with specific 
activation antibodies. Pretreatment of cells with agonists for the cannabinoid receptor 
type 2 (CB2) (receptors for endocanabbinoids that exert various cardiovascular and 
anti-inflammatory effects) diminished activation of the MAPK pathway (Rajesh, M v et 
a/., 2008). Kim, et a/., studied the effect of magnolol, an active component extracted 
from Magnolia officinalis that acts as an inhibitor to the development of 
atherosclerotic disease. Their experiments showed that TNF-a stimulated cell 
proliferation, as measured by cell viability and DNA synthesis assays, and ERK1/2 
activation as assayed by immunoblot analyses, and magnolol reduced the rate of cell 
viability and thymidine incorporation, as well as the ERK1/2 activation (Kim, H.M., et 
a/., 2007). Zhang, et a/., studied the effect of notoginsenoside R1, the main ingredient 
of P. notoginseng used in China for the prevention and management of 
cardiovascular disease, on migration and fibronectin production in human aortic 
smooth muscle cells. Their results show that TNF-a increased activation of all three 
MAPKs pathways, ERK1/2, JNK, and p38 using Western Blot, and that pretreatment of 
cells with notoginsenoside R1 resulted in a significant inhibition of TNF-a-induced 
phosphorylated-ERK1/2 pathway (Zhang, H.S., et a!., 2006). Another study by the 
same author, states that ginsenoside Rgl, one of the active ingredients of the Chinese 
herbal medicine ginseng, exhibits a variety of cardiovascular actions including an 
antihypertensive effects. Their objective was to determine if ERK1/2, p38 and JNK 
signaling pathways are involved in ginsenoside Rgl-inhibted HASMC proliferation.
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For that purpose, cells were treated with specific pharmacological inhibitors for those 
pathways along with ginsenoside, and proliferation studies were performed using the 
CellTiter 96 Cell Proliferation Assay. Their findings show that TNF-a stimulated cell 
proliferation and ginsenoside inhibited that proliferation, also, the ERK1/2 inhibitors 
decreased HASMCs proliferation and p38 and JNK inhibitors did not affect this 
process on TNF-a-treated HASMCs (Zhang, H.S., et a/., 2006).
1.2 Atherosclerosis and Restenosis:
Atherosclerosis is a chronic inflammatory disease that is characterized by the 
accumulation of lipids and fibrotic tissue along the walls of arteries. The first lesion of 
this pathology is the fatty streak, which comprises an area of intimal thickening mainly 
formed by macrophages with accumulation of lipids called "foam cells", lymphocytes 
and smooth muscle cells forming the fatty streak (Faggiotto, A., et a/., 1984). As the 
lesion continues, this tissue develops into more advanced complex lesions called the 
fibrous plaques, which can increase in size and expand into the arterial lumen 
obstructing the blood flow (Ross, R., 1993). Restenosis is a maladaptive response of 
the coronary artery to trauma induced during angioplasty consisting of thrombosis, 
inflammation, smooth muscle cell proliferation and migration, and extracellular
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matrix production that together contribute to lumen loss after approximately 6 
months of the procedure (Nikol, Sv ef a/., 1996).
Several studies have shown that inflammatory cells present in the blood such as 
monocytes and/or macrophages have a very important role in the development of 
atherosclerosis. Tissue culture studies using vascular cells and monocytes/ 
macrophages suggested different pathways for disease initiation and progression. The 
endothelium plays also a very important role since it is the first cell layer involved in 
the atherosclerotic process. The endothelium functions as a selectively permeable 
barrier between blood and tissues. It has both sensory and executive functions, and 
can generate effector molecules that regulate thrombosis, inflammation, vascular tone 
and vascular remodeling (Lusis, A.J., 2000).
Atherosclerotic lesions begin when high levels of LDLs are present and they 
accumulate in the subendothelial matrix diffusing through epithelial cell junctions. 
Then, oxidized LDL stimulates endothelial cells to produce a number of pro- 
inflammatory molecules, including adhesion molecules such as ICAM-1, P-selectin, E- 
selectin, PCAM-1 and VCAM-1, chemotactic proteins such as monocyte chemotactic 
protein-1 (MCP-1), and growth factors such as macrophage colony-stimulating factor
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(M-CSF), resulting in the recruitment of monocytes to the vessel wall. The entry of 
particular types of leukocytes into the artery wall is mediated by adhesion molecules 
and chemotactic factors. The rolling of leukocytes along the endothelial surface is 
mediated by selectins which bind to ligands on leukocytes. The firm adhesion of 
monocytes and T cells to the endothelium can be mediated by the integrin VLA-4 on 
T-cells, which interacts with VCAM-1 on the endothelium (Lusis, A.J., 2000; Shih, 
P.T., et a/., 1999).
T cells are present in all stages of the atherosclerotic process. T-cell activation occurs 
when T-cells bind to antigens presented by macrophages causing them to secrete 
cytokines including interferon-y (IFN-y) and TNF-a, producing the inflammatory 
response (Lusis, A.J., 2000; Ross, R., 1993; Tedgui, A., et a!., 2006). T-cell activation 
is also mediated by interleukin 2 (IL-2), and granulocyte-macrophage colony- 
stimulating factor. Lymphocytes enter the intima facilitated by binding to adhesion 
molecules including VCAM-1 and in response to chemoattractants selective for 
lymphocytes such as interferon-y (IFN-y). These chemokines bind to chemokine 
receptors (CXCR3) expressed by T cells in the atherosclerotic lesion where they can 
interact with antigens such as ox-LDL and heat shock proteins (HSPs). Then, after 
contact of the receptor with the antigen, the T cell can produce cytokines that can
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influence the behavior of other cells present in the atheroma (Libby, P., 2002; 
Tedgui, A., et a/., 2006).
Highly oxidized aggregated LDL (oxLDL) is formed in the vessel as a result of the 
action of reactive oxygen species (ROS) and the enzymes sphingomyelinase (SMase), 
secretory phospholipase 2 (sPLA2), other lipases, and myeloperoxidase (MPO). The 
oxidized aggregated LDL is recognized by macrophage scavenger receptors whose 
expression is mediated by cytokines such as TNF-a and interferon-y (IFN-y) forming 
the foam cells (Libby, P., 2002; Lusis, A.J., 2000). Foam cells secrete apolipoprotein E 
(apoE), which may facilitate removal of excess cellular cholesterol. The death of foam 
cells leaves behind a growing mass of extracellular lipids and other cell debris (Libby, 
P., 2002; Lusis, A.J., 2000; Ross, R., 1999).
The fibrotic plaques in atherosclerosis are formed by a dense cap of connective tissue 
mainly formed by SMC, a core of lipid and necrotic debris, macrophages, SMCs and 
T lymphocytes. Cytokines and growth factors secreted by macrophages and T cells 
are important for SMC migration and proliferation and extracellular matrix 
production. In this process, there is migration of SMC from the media to the intima 
that is stimulated by different molecules such as the platelet derived growth factor
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(PDCF), fibroblast growth factor 2 (FGF-2) and transforming growth factor beta (TGF- 
P) (Lusis, A.J., 2000; Ross, R., 1993; Tedgui, A., eta/., 2006)..
In the advanced lesions, vulnerable plaques have an increased number of 
inflammatory cells and thin fibrous caps which are the result from production and 
degradation of matrix by various proteases such as collagenases, gelatinases, 
stromolysin and cathepsins and by inhibition of matrix secretion. Products of 
inflammatory cells are likely to influence this processes. For example, T cells produce 
IFN-y, which inhibits the production of matrix by SMCs, and macrophages produce 
various proteases that degrade extracellular matrix. Rupture frequently occurs at the 
lesion edges where the fibrotic cap is thin and rich in foam cells, suggesting that 
factors contributing to inflammation may also influence thrombosis (Lusis, A.J., 2000; 
Libby, P., 2000).
Platelets are important in maintaining vascular integrity in the absence of injury and 
protecting against spontaneous hemorrhage. In the atherosclerotic plaque, activated 
platelets can accumulate on the walls of arteries and recruit additional platelets into 
an expanding thrombus contributing to the obstruction of blood flow (Ross, R., 1999). 
Plaque rupture and thrombosis are notable complications of advanced lesions that
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lead to unstable coronary syndromes or myocardial infarction (Ross, R., 1993; Fuster, 
Vv et a/., 2005).
1.3 Smooth muscle cells in atherosclerosis:
SMCs are highly specialized cells whose principal function is contraction and 
regulation of blood vessel tone and diameter, blood pressure, and blood flow 
distribution. Normally, they proliferate at a very low rate, exhibit very low synthetic 
activity, and express contractile proteins, ion channels, and signaling molecules 
required for their contractile function. They also are very flexible and can undergo 
changes in phenotype in response to changes in the local environment. In response to 
vascular injury, SMCs proliferate faster, migrate and produce more extracellular 
matrix production playing a very important role in vascular repair.
1.3.1 Migration: SMCs migrate from the media to the intima. As mentioned before, 
oxLDL stimulates production of MCP-1 that contributes to the formation of foam 
cells. Macrophages produce PDGF and other growth factors that encourage SMC to 
migrate through and around foam cells to produce the fibrous cap (Libby, P., 2000;
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Newby, A.C., et a/., 1999). This leads to platelet adherence and release, leading to 
early replication of SMCs in the media contributing to intimal thickening and 
posterior lesion growth (Raines, E.W., et a/., 1993).
Several studies have focused on the effect of TNF-a in migration of SMC using 
different techniques. Some of them used migration through porous membranes and 
some other ones used the Matrigel migration assay in which cells migrate through a 
matrigel-coated filter towards a chemoattractant substance (Chung, T.W., et a/., 
2004). In both techniques after a period of incubation, migrated cells are fixed, 
stained and counted. The results found by several authors are consistent in the fact 
that TNF-a increases migration of SMC (Ha, K.T., et a/., 2004; Jin, U.H., et a/., 2006; 
Fee, S.O., et a/., 2006). Another technique used is the scratch wound assay, in which 
a scrape is made with a sterile single-edged razor blade, then cells are incubated in 
conditioned media, fixed and the distance that cells had migrated across the edge of 
the "wound" is measured. Also, results show an increase of migration when cells are 
treated with TNF-a (Kim, H.S., et a/., 2007; Fi, H., et a/., 2007). Taken together, 
these results suggest the involvement of TNF-a in the progression of atherosclerosis 
through activation of cell migration.
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1.3.2 Proliferation: Analyses of SMC proliferation in atherosclerotic lesions indicate 
that replication rates are very low. It has been suggested that this low proliferative 
level could be due to a greater role for the migration of cells from the media into the 
intima (Raines, E.W., et a/., 1993). However, growth regulatory molecules can, in 
some cases, inhibit proliferation while in other cases they can stimulate it. Some 
molecules that induce cell proliferation that are not normally in the arterial wall 
include PDGF, FGF, insulin-like growth factor 1 (IGF-1), IL-1, TNF-a and TGF-P 
(Ross, R„ 1993).
One of the most widely techniques to study cell proliferation is the [3H]thymidine 
incorporation, which uses indirectly thymidine kinase (an enzyme present in the 
cytoplasm only in anticipation of cell division) in order to identify dividing cells by 
incorporation of radiolabeled thymidine in DNA and subsequent measurement of the 
radioactivity by liquid scintillation (Nanda, D., et a/., 2001). For this purpose, tritiated 
thymidine is included in the growth medium and the incorporation into DNA is 
measured. As mentioned above, TNF-a is involved in SMC proliferation but 
investigation reports are conflicting, showing that TNF-a increases vascular SMC 
proliferation (Kim, H.M., et a/., 2007; Moon, S.K., et a/., 2003; Moon, S.K., et a/., 
2007) or could not exert any effect on DNA synthesis (Goetze, S., et a/., 1999; 
Peppel, K., et a/., 2005).
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1.3.3 Phenotypic modulation: SMC are responsive to abnormal environmental signals 
that can lead to adverse phenotypic switching and acquisition of some properties that 
can contribute to the progression of atherosclerosis (Owens, G.K., 1995; Owens, 
G.K., et al., 2004). Normally, medial SMC show a contractile phenotype, in which 
layers of SMCs are arranged in a concentric way. In atherosclerosis, SMCs show 
synthetic characteristics, showing reduced expression of a-actin, have a higher 
proliferative index and produce more extracellular matrix, proteases and cytokines 
than contractile SMCs (Campbell, J.H., et al., 1994). It has been shown that TNF-a 
can modulate the phenotype of aortic SMCs, after incubation of SMCs with TNF-a. In 
this study, cultured rabbit aortic SMCs from an atheroma and SMCs from normal 
media (M-SMC) were treated with TNF-a. Results show that SMCs from atheroma 
plaques differed phenotypically from M-SMC in their growth rate, secretion of SMC- 
derived growth factor (SDGF), and metabolism of acetylated low density lipoproteins 
(a-LDL). SMC from the atheroma grew faster than control cells and secreted a 
substantial amount of SDGF. These findings suggest that TNF-a is important in the 
pathogenesis of atherosclerosis (Morisaki, N., et a/., 1993).
1.3.4 Synthesis and degradation of matrix components: One of the major roles of 
smooth muscle cells is to produce extracellular matrix, which accumulates over the 
course of the development of atherosclerotic lesions (Falk, E., 2006). Atherosclerotic
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lesions tend to contain mostly proteoglycans with scattered type I collagen fibrils and 
fibronectin, altering the architecture of the vessel and the proliferative index (Ross, R., 
1999). The increased deposition of collagen in atherosclerosis alters the mechanical 
properties of the wall, making it more susceptible to changes in the blood flow 
(Raines, E.W., et a/., 1993). The role of the SMC varies depending on the stage of the 
disease, playing a role stabilizing plaques before activation of protease cascades that 
may contribute to the plaque rupture (Owens, G.K., et a/., 2004; Galis, Z.S., et a/., 
2002). Changes in the SMCs include also production of various proteases allowing 
vascular remodeling and repair (Galis, Z.S., et a/., 2002). Degradation of extracellular 
matrix (ECM) enables cells to migrate and proliferate (Raffetto, J.D., et a/., 2008).
Numerous studies have evaluated the effect of TNF-a on MMPs expression. The best 
known proteases involved in atherosclerosis are the Type IV collagenases or 
gelatinases, including gelatinase-A (MMP-2) and gelatinase-B (MMP-9) that digest 
denatured collagens (Newby, A.C., et a/., 2000). MMP-2 is constitutively expressed 
by several cell types, including SMCs and its expression is not stimulated by cytokines, 
whereas MMP-9's basal levels are very low and its expression can be induced by 
cytokines such as TNF-a (Moon, S.K., et a/., 2003; Fabunmi, R.P., et a/., 1996; Galis, 
Z.S., et a/., 1994). MMP-9 gene expression can be assessed by Northern blot or Real 
Time PCR, and MMP-9 enzymatic activity can be detected by zymography which is
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an electrophoretic technique, based on SDS-PAGE that includes gelatin as a substrate 
copolymerized with the polyacrylamide gel. After the procedure, the gel is stained 
and areas of digestion appear as clear bands against a darkly stained background 
where the substrate has been degraded by the enzyme (Overall, C.M., et a/., 1989). 
These protocols, however, are subject to many adjustments in order to optimize the 
technique and are very difficult to reproduce. The effect of TNF-a on SMCs has been 
described by both techniques concluding that MMP-9 is stimulated by TNF-a (Moon, 
S.K., et a/., 2004; Cho, A., et a/., 2000; Kim, H.M., et a/., 2007; Ha, K.T., et a/., 
2004; Jin, U.HV et a/., 2006; Fee, S.O., et a/., 2006; Kim, H.S., et a/., 2007; Fi, H., et 
a/., 2007; Moon, S.K., et a/., 2003; Moon, S.K., et a/., 2007; Fee, C.W., et a/., 2007; 
Moon, S.K., et a/., 2004; Suh, S.J., et a/., 2006). Novel therapeutic agents target this 
matrix metalloproteinase giving it a very important role in atherosclerosis.
1.3.5 Inhibitory studies of TNF-a: As mentioned above, TNF-a promotes the 
development of atherosclerotic lesions by stimulating inflammatory cells and by its 
ability to directly modulate vascular SMCs. Its effects on SMC include promotion of 
proliferation, migration and elaboration of MMPs (Fibby, P., 2002). These effects are 
mediated by two distinct receptors, TNFR1 (p55) and TNFR2 (p75). Almost all cell 
types express at least one of the two kinds of TNF-a receptors. The two receptors 
display no significant homology in their intracellular domains and they can elicit
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different intracellular signals. To evaluate the importance of TNF-a in atherosclerosis, 
TNF-a receptor knockout mice studies had been designed. It has been shown that 
TNFR1 knockout mice are moderately resistant to the effect of lipopolysaccharides 
whereas TNFR2 knockout mice are moderately resistant to the lethal effect of TNF-a 
itself (Liu, Z.C., et a!., 2001). In atherosclerosis, blockage of TNFR1 results in a 
decrease in the acceleration of lesion development indicating that TNF-a plays an 
important role in the development of atherosclerosis (Campbell, L.A., et al., 2005). 
The ApoE null mouse model of atherosclerosis contains lipid laden foam cells and 
appreciable atherosclerosis is noted in these mice after maintaining them on a high 
fat diet. Mice deficient in both ApoE and TNF-a exhibited a reduction of relative 
lesion size after 10 weeks of high fat diet. These findings demonstrate that TNF-a is 
actively involved in the progression of atherosclerosis (Branen, Lv et a/., 2004).
Studies in SMC using antibodies to neutralize TNFR1 show that this inhibition blocks 
MAPK activation by TNF-a, whereas neutralization of TNFR2 had no effect. In 
vascular SMC, TNF-« induces signaling through the TNFR1 that leads to MAPK 
activation, which is required for cell migration (Goetze, S., et a/., 1999). Other studies 
had shown that TNF-a promotes macrophage-induced vascular SMC apoptosis and 
that blockade of TNFR1 and TNFR2 each inhibited vascular SMC apoptosis (Boyle,
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J.JV et a!., 2003). A summary of the most important processes in atherosclerosis is 
depicted in Figure 2.
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Schematic representation of the process of atherosclerosis.
Figure 2.
23
Schematic representation of the process of atherosclerosis.
The figure represents the process of atherosclerosis. Progress of the disease is 
represented from left to right. The first changes to occur take place in the 
endothelium where permeability to lipoproteins is increased by reactive oxygen 
species. There is up-regulation of leukocyte adhesion molecules, endothelial 
adhesion molecules and vascular cell adhesion molecules; and migration of 
leukocytes into the artery wall. Then, lipid-laden monocytes, macrophages (also 
called foam cells) and T cells begin forming the fatty streak. Later they are joined by 
smooth muscle cells. In this process there is also smooth muscle migration, which is 
stimulated by PDGF, FGF-2, and TGF-P; T-cell activation, which is mediated by TNF- 
a, IL-2, and granulocyte-macrophage colony-stimulating factor; foam-cell formation, 
which is mediated by oxLDL, macrophage colony-stimulating factor, TNF-a and IL-1; 
and platelet adherence and aggregation, which are stimulated by integrins, P-selectin, 
fibrin and thromboxane A2. Later, fatty streaks progress to form intermediate and 
advanced lesions mainly formed by a fibrous cap. This cap contains a mixture of 
leukocytes, lipid, and debris, which form a necrotic core which is the result of cell 
apoptosis and necrosis, increased proteolytic activity, and lipid accumulation. The 
fibrous cap forms as a result of increased activity of PDGF, TGF-p, IL-1, TNF-a, and 
of decreased connective tissue degradation. Finally, rupture of the fibrous cap of the
Figure 2.
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fibrous plaque can lead to thrombosis. This often occurs in sites where the fibrous cap 
is thin. Thinning of the fibrous cap is due to the continuous influx and activation of 
macrophages which release metalloproteinases and other proteolytic enzymes at 
these sites.
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1.4 Lysyl oxidase:
Lysyl oxidase (LOX) catalyzes the oxidative deamination of peptidyl lysine and 
hydroxylysine in collagen, and peptidyl lysine in elastin to the corresponding peptidyl 
aldehydes, which then spontaneously form covalent cross-links (Martin, G.R., and 
Pinnell, S.R., 1968). LOX, therefore, plays an important role in the morphogenesis 
and repair of connective tissues of the cardiovascular, respiratory, skeletal, and other 
systems of the body (Kagan, H.M., et a/., 2003).
1.4.1 LOX synthesis and proteolytic processing: LOX is synthesized as an N- 
glycosylated 50 kDa pro-protein (proLOX) and secreted into the extracellular 
environment, where it is cleaved by procollagen C-proteinase resulting in 32 kDa 
functional enzyme and an 18 kDa propeptide (Trackman, P.C., et a!., 1992; 
Panchenko, M.V., et a/., 1996; Uzel, M.I., et a/., 2001; Palamakumbura, A.H., et a/., 
2002). It has also been found that other extracellular proteases, including mammalian 
tolloid and tolloid-like 1 and 2 proteases, also cleave proLOX at the correct 
physiological site but at lower efficiency (Uzel, M.I., et a/., 2001).
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1.4.2 Localization of LOX: LOX is localized in the extracellular compartment of 
several tissues, including skin, aorta, heart, lung, liver, and cartilage (Kagan, H.M., et 
a/., 1986; Hayashi, K., et a/., 2004). It is also known that LOX is widely expressed by 
many cell types including fibroblasts, aortic and lung smooth muscle cells, 
myofibroblasts, kidney epithelial cells, osteoblasts, endothelial cells and chondrocytes 
(Wakasaki, H., et a/., 1990; Csiszar, K., 2001).
At the subcellular level, LOX has been found intracellularly along a cytoskeletal 
protein-like structure in fibroblasts detected by immunofluorescence (Wakasaki, H., 
et a/., 1990). Li et a/., using polyclonal LOX antibodies and confocal microscopy 
found that LOX was within the nuclei of rat vascular smooth muscle cells and within 
nuclei of 3T3 fibroblasts as well (Li, W., et a/., 1997).
1.4.3 Functions: Lysyl oxidase is an amine oxidase. Copper and a peptidyl quinone 
carbonyl cofactor are both essential for its enzymatic activity. Copper in LOX seems 
to be involved in the electron transfer to and from oxygen to promote the oxidative 
deamination of peptidyl lysyl groups in the precursors of collagen and to internally 
catalyze the quinine cofactor formation. The oxidation of peptidyl lysine residues 
ends in the formation of peptidyl a-aminoadipic-5-semialdehyde that once formed
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can condense spontaneously with neighboring aldehydes or e-aminogroups to form 
cross-links. These intermediates can further condense with each other and generate 
more complex cross-links in collagen or elastin chains, including desmosine, 
pyridinoline, and pyrrole cross-links (Kagan, H.M., et a/., 1991; Siegel, R.C., 1974; 
Rucker, R.BV et al., 1998). Collagen and elastin are stabilized by these covalent cross­
links. Normal cross-links are also required for the formation of functional and mature 
collagen and elastin (Kagan, H.M., et al., 1991; Knott, L., et al., 1998; Bedell-Hogan, 
D., et al., 1993). Figure 3 shows the LOX reaction.
Abnormal expression of LOX is associated with different diseases. In vivo studies have 
shown that animals under a copper-deficient diet or with |3-aminopropionitrile (|3- 
APN) a specific inhibitor of LOX, exhibited lathyrism, characterized by poor bone 
strength, deformity of bones and joints, hyperextensible skin, weak ligaments and 
vascular aneurysms (Selye, H., 1957; Eyre, D.R., Paz, M.A., and Gallop, P.M., 1984). 
Therefore, LOX plays a critical role in maintaining the homeostasis of the connective 
tissues of the body.
28
Figure 3
Lysyl oxidase reactions.
A. Lysyl oxidase catalyzes the oxidative deamination of lysine/hydroxylysine residues
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B. Cross-link formation:
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Figure 3
Lysyl oxidase reactions.
A. Lysyl oxidase catalyzes the oxidative deamination of lysine/hydroxylysine 
residues.
Lysyl oxidase catalyzes the oxidative deamination of lysine or hydroxylysines in 
collagen, and lysine in elastin to the corresponding aldehydes.
B. Cross-link formation.
Lysyl oxidase catalyzes the oxidative deamination of peptidyl lysine and 
hydroxylysine to the corresponding peptidyl aldehydes. The aldehyde residue can 
then spontaneously condense with neighboring aldehydes or e-amino groups to form 
cross-links, for example, Schiff bases or aldol condensation products. These 
intermediates can further condense with each other and generate more complex 
cross-links in collagen or elastin chains, including desmosine, pyridinoline, and 
pyrrole cross-link.
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1.4.4 Lysyl oxidase and cardiovascular diseases: Excessive accumulation of insoluble 
collagen fibers leads to fibrosis, and up-regulation of LOX expression and increased 
LOX activity is found in several fibrotic diseases such as scleroderma 
(Palamakumbura, A.H., et a/., 2002; Kagan, H.M., 2000; Trivedy, C., et a/., 1999). 
Atherogenic levels of low-density lipoproteins could down-regulate LOX expression 
in vascular endothelial cells causing an increase in endothelial permeability 
contributing to atherosclerotic plaque formation, possibly through alteration of the 
endothelial extracellular matrix composition (Rodriguez, Cv et a/., 2002). Lysyl 
oxidase knock-out mice showed increased immature cross-links and fragmented 
collagen and elastic fibers, leading to ruptured arterial aneurysms, diaphragmatic 
rupture, cardiovascular dysfunction and perinatal death (Maki, J.MV et a/., 2002). 
Histological studies revealed fragmentation of elastic fibers, disruption of VSMC and 
alterations on endothelial cell morphology (Hornstra, I.K., et a/., 2003). It has also 
been reported that LOX enzyme activity and expression are increased in 
atherosclerosis and in models of restenosis. Brasselet et al., investigated the effect of 
cross-linking inhibition in collagen, elastin, and arterial remodeling after balloon injury 
in the atherosclerotic rabbit model. LOX inhibition was achieved by feeding rabbits 
with P-APN and compared with untreated animals. They found that the animals fed 
with the LOX inhibitor showed a profound disorganization of collagen fibers in 
arteries when compared to the control animals. They also found that LOX inhibition 
reduces restenotic rates and causes a lower constrictive remodeling compared with
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control animals suggesting that collagen and elastin cross-linking play a role in the 
healing process via constrictive remodeling and restenosis after balloon injury 
(Brasselet, Cv et a/., 2005).
Using a rat model of arterial balloon injury, Nuthakki et a/., by means of mRNA 
quantitation and immunohistochemical analysis, found that LOX expression in 
balloon-injured arteries increased significantly by day 3 after injury, and remained 
elevated through day 21, with a decrease toward baseline levels by day 28. Lysyl 
oxidase protein expression reached its maximum levels at day 14, and remained until 
day 28. Collagen accumulation reached its maximum levels day 28, corresponding to 
the maximal increase in intimal area, concluding that LOX mRNA and protein 
expression has a time dependent effect after balloon injury of rat carotid artery and 
that this expression appears to precede maximal collagen accumulation. This suggests 
that LOX may have an important role in stabilization of collagen and elastin at sites of 
vascular injury and that modulation of LOX activity may be a viable method to 
prevent or reduce restenosis (Nuthakki, V.K., et a/., 2004).
Recent studies about LOX have suggested that it can contribute to other important 
biological functions in addition to the induction of cross-links in collagen and elastin. 
Kenyon et a/., demonstrated that the LOX gene could work as an anti-oncogene of
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ras meaning that it could have tumor suppressor activity (Kenyon, K., et a/., 1991). 
Reduced LOX expression was observed in prostate cancer, colorectal cancer, and 
head and neck carcinoma (Csiszar, K., et a/., 2002). Giampuzzi et a/., reported that 
normal kidney fibroblast cells (NRK-49F) became transformed by transfection with 
LOX (Giampuzzi, M., et a/., 2001; Giampuzzi, M v et a/., 2003). Later on, Jeay et a/., 
transfected ras-transformed NIH 3T3 cells with the full length of LOX proenzyme and 
found that its overexpression could inhibit ras-induced NF-kB binding and 
transcriptional activity by inhibiting the PI3K/Akt and Raf/MEK signaling pathways 
(Jeay, Sv et a/., 2003). Taken together, all these data, suggest that LOX has various 
important biological functions.
1.4.5 Lysyl oxidase pro-peptide (LOX-PP); The 18-kDa Lysyl oxidase pro-peptide 
(LOX-PP) is generated from the 50-kDa pro-LOX by extracellular proteolytic cleavage 
during the biosynthesis of the active 30-kDa LOX enzyme. The rat LOX-PP contains 
141 amino acids, and the calculated molecular weight is 14.9 kDa (Kagan, H.M., et 
a/., 2003).
There are only a few studies that evaluate the biological functions of the LOX-PP. 
One of the first studies by Kagan et a!., showed that Chinese hamster ovary cell
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clones transfected with a truncated LOX cDNA construct that had deleted the LOX-
PP region, could still secrete active mature LOX (Kagan, H.M., et al., 1995). In 
contrast, myofibroblasts were transfected with a more complete deletion construct, 
showed no secreted LOX in the cell medium, which suggested that LOX-PP is 
important in the secretion of LOX (Seve, S., et a/., 2002).
Recent studies from our lab suggest that the LOX-PP could induce the phenotypic 
reversion of the ras-transformed fibroblast cells. Ras-transformed NIH 3T3 cells 
(RS485) and an anti-sense LOX stable clone were grown on recombinant LOX-PP 
coated plates. Both demonstrated inhibited cell growth and altered cell cycle 
progression, with increased cell percentage in G1 phase and decreased cell 
percentage in S phase. Moreover, recombinant LOX-PP, and not LOX, showed strong 
inhibition of RS485 cell growth by colony formation assay. These results suggest that 
the LOX-PP inhibits specifically ras-dependent cell transformation. Next, the signaling 
pathways involved were investigated. RS485 cells and NIH3T3 cells were transiently 
transfected with LOX-PP expression vector or empty vector and NF-KB-dependent 
luciferase reporter plasmid. Results showed that LOX-PP transfection inhibited the 
luciferase activity in RS485 cells to control levels, however, this effect was blocked in 
the presence of constitutively active Akt suggesting that LOX-PP inhibited ras-
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dependent cell transformation through the PI3K/Akt pathway (Palamakumbura, A.H., 
et a/., 2004).
The next study by Min et a/., shows that LOX-PP inhibits transformation of breast 
cancer cells driven by Her-2/neu, an upstream activator of Ras. They have found that 
LOX-PP was strongly inhibitory in soft agar colony formation of mouse mammary 
tumor virus (MMTV)-Her-2/neu cell line NF639, and MMTV-v-H-ras cell line SHI-1 
concluding that the LOX-PP inhibits anchorage-independent growth induced via Ras 
signaling in breast cancer cells. Then, they studied the effects of LOX-PP on Akt and 
ERK1/2 activation finding that the LOX propeptide suppresses the activation of Akt 
and ERK1/2 in NF639 breast cancer cells concluding that LOX-PP effectively reduces 
Her-2/neu-mediated activation of Akt and Erk in NF639 breast cancer cells. Then, 
they examined the effects of LOX-PP on NF-kB activity in NF639 cells and found a 
reduction in NF-k B binding. Taken together, these data indicate that LOX-PP 
suppresses downstream targets mediating transformation by oncogenic Her-2/neu. 
Then, they wanted to determine whether LOX-PP expression can inhibit the invasive 
properties of Her-2/neu breast cancer cells so NF639-EV and NF639-LOX-PP cells 
were subjected to a migration assay. Expression of LOX-PP reduced migration of 
NF639 cells. Next, the effects of LOX-PP on the ability of highly malignant NF639 
cells to form invasive, branching colonies in Matrigel were investigated. NF639-EV
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cells formed the typical branching, invasive colonies seen with NF639 cells after 5 
days in culture in Matrigel. The expression of LOX-PP prevented the formation of 
these structures and only small round colonies were observed with NF639-LOX-PP 
cells, hence, LOX-PP promotes a less invasive phenotype and reverses EMT in Her- 
2/neu breast cancer cells. Finally, they evaluated if LOX-PP suppresses Her-2-driven 
tumor formation in vivo by injection of newly infected populations of NF639 cells 
with either the EV or LOX-PP. Tumors developed only slowly in both populations; 
however, by day 17, the tumors resulting from the EV-infected NF639 cells began to 
grow at a faster rate and were notably larger than those expressing LOX-PP, 
concluding that LOX-PP suppresses FHer-2/neu-driven tumor formation in vivo (Min,
C., et al., 2007).
The last study evaluates the repression of BCL2 by the tumor suppressor activity of 
the LOX-PP in the inhibition of lung and pancreatic cancer cells. For that purpose, 
investigators evaluated if the LOX-PP functions in human lung and pancreatic cancer 
cells that carry NRAS and KRAS mutations of the members of the RAS gene family, 
respectively. It was found that LOX-PP inhibited anchorage-independent growth and 
invasive colony for mation by HI 299 lung cancer cells by means of transfection of 
H I299 cells with vectors that expressed LOX-PP and growth of H I299 cells in soft 
agar where the cell growth was increased. Ectopic expression of LOX-PP reduced the
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ability of HI 299 cells to grow in soft agar. It was also found that LOX-PP inhibits RAS 
signaling pathways in lung cancer cells using immunoblotting for the active form of 
Akt and ERK proteins. LOX-PP also reduces RAS-mediated transformation of 
pancreatic cancer cells as evaluated by immunoprecipitation followed by 
immunoblotting of cell medium. LOX-PP down-regulates NL-kB in pancreatic cancer 
cells and Bcl-2 is an essential target for LOX-PP signaling in pancreatic and lung 
cancer cells (Wu, M., et a/., 2007). Taken together, these data suggest that the LOX- 
PP has anti-tumoral effects and could serve as a therapeutic agent.
1.4.6 Lysyl oxidase isotypes: Recently, in addition to LOX itself, four other "lysyl 
oxidase-like" genes have been described: LOXL1, LOXL2, LOXL3 and LOXL4 named 
in the order in which they were discovered. They encode for proteins of the same 
name that are expressed in vascular tissues. These proteins are fully functional but 
genetically distinct from LOX, indicating that collagen cross-linking may be regulated 
by a complex mechanism involving multiple LOX isoforms and not only one. These 
proteins may have novel functions that include cell adhesion, cell growth control, 
tumor suppression, senescence and chemotaxis (Molnar, )., et al., 2003).
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Each member of the LOXL protein family is characterized by a conserved amino acid 
sequence at their C-terminal end including the copper binding site, residues for 
carbonyl co-factor formation, and the cytokine receptor-like domain.
The first lysyl oxidase-like protein described is LOXL1, a 63 kDa polypeptide 
(Kenyon, Kv et al., 1993; Kim, Yv et al., 1999). Similar to LOX, studies have 
suggested that this protein can also be cleaved proteolytically by procollagen C- 
proteinase (BMP-1) or mammalian tolloid proteinases (Uzel, M.I., et al., 2001; Borel, 
A., et al., 2001). (3-aminopropionitrile (P-APN) inhibits LOXL1 activity (Molnar, )., et 
al., 2003; Borel, A., et al., 2001).
Recent studies of LOX and LOXL1 distribution in tissues have shown a large degree of 
co-localization of both enzymes. Heart, lung, and skin, for example, have overlapping 
localization of LOX and LOXL1 (Csiszar, K., 2001). LOXL1 seems to use tropoelastin 
as a substrate. Knockout mouse studies have shown that the decreased elastin 
content in the LOX knockout mice results in death shortly after birth due to aortic 
dissection, cardiovascular dysfunction, and diaphragmatic rupture. Ultrastructural 
analysis shows poorly developed, fragmented, and discontinuous elastic fibers in 
aorta, lung, and skin. LOXL1 null mice, in contrast, have a mild connective tissue
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phenotype characterized by pelvic laxity in female animals and enlarged pulmonary 
airspaces that result from decreased elastin content (Thomassin, L., et al., 2005). In 
addition, the LOXL1 null mice do not deposit normal elastic fibers in the postpartum 
uterus, had a lower urinary tract dysfunction and showed pelvic organ prolapse (Liu, 
Gv et al., 2007).
Lysyl oxidase-like 2 (LOXL2) (Saito, Hv et a/., 1997; Jourdan-Le Saux, C., et al., 
1999), is an 87 kDa polypeptide. It is expressed in senescent fibroblasts and several 
adherent tumor cell lines, but is down-regulated in several non-adherent tumor cells, 
suggesting that it may be involved in cell adhesion giving it a role in metastasis (Saito, 
Hv et al., 1997). The tissue distribution of LOXL2 is different from LOX and LOXL1, it 
does not overlap very much. Reports so far suggest that LOXL2 is mostly present in 
reproductive tissues such as prostate, uterus and placenta. It has also been detected 
in human mammary epithelial cell extracts and in placental tissues. Due to its 
localization, it is believed that it may be associated with the basement membrane, 
potentially with basement membrane collagen type IV (Csiszar, K., 2001).
Lysyl oxidase like 3 (LOXL3) (Maki, J.M., et al., 2001; Asuncion, Lv et al., 2001) is a 
97 kDa polypeptide. The extracellular location of the LOXL3 protein and the
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presence of four Scavenger Receptor Cysteine-Rich (SRCR) domains suggest that 
LOXL3 may be involved in binding and crosslinking to other cell-surface and 
extracellular-matrix proteins. The highest expression levels among these tissues are 
being seen in the placenta, heart, ovary, testis, small intestine and spleen (Maki, J.M., 
et a/., 2001).
Lysyl oxidase-like 4 (LOXL4) (Maki, J.M., et a/., 2001) is a 97 kDa protein. It shows a 
significant overall similarity to LOXL2 and LOXL3. The N-terminal region contains 
four SRCRs, also characteristic of the LOXL2 and LOXL3 and is likely to be involved 
in binding to other cell surface and extracellular matrix molecules. LOXL4 is 
expressed in many human tissues, the strongest expression levels are in skeletal 
muscle, testis and pancreas. Recombinant expression of the LOXL4 protein was 
studied and results suggest that LOXL4 is a secreted extracellular matrix protein 
(Maki, J.M., et a/., 2001). The human LOXL4 protein shows very high similarities to 
the reported murine cartilage LOXC protein indicating that these two cDNAs encode 
the same protein in distinct species. Expression of LOXL4 mRNA was detected in 
osteoblastic MC3T3-E1 cells and embryonic fibroblast C3EH10T1/2 cells, whereas 
fibroblasts and myoblastic cells did not express LOXL4 mRNA in vitro. The mRNA 
levels of LOXL4 increased throughout the process of chondrogenic differentiation in 
ATDC5 cells. LOXC gene expression was localized in hypertrophic and calcified
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chondrocytes of growth plates in adult mice. They also showed that LOXL4 can be 
inhibited by P-APN. These results suggest that LOXL4 is expressed in cartilage and it 
can modulate the formation of a collagenous extracellular matrix (Ito, Hv et al., 
2001).
Similarities between LOXL2, LOXL3 and LOXL4 are that they have the same 
conserved sites as LOX and LOXL1, but also contain SRCR domains that could play a 
role in cell adhesion and protein-protein interactions (Csiszar, K., 2001).
Figure 4 shows the domain structures of LOX and the four LOXL isotypes.
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Figure 4.
Domain structures of murine lysyl oxidase and LOXL1 -  LOXL4.
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Adapted from the NCBI protein graphics database for murine LOX, LOXL1, LOXL2, 
LOXL3 and LOXL4.
Figure 4.
Domain structures of murine lysyl oxidase and LOXL1 -  LOXL4.
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1.5 TNF-a and lysyl oxidase studies:
Little information is known about the role of TNF-a in the regulation of LOX and its 
isotypes. The first report by our laboratory (Pischon, Nv et a/., 2004) shows that in 
osteoblasts, TNF-a decreases collagen deposition without decreasing collagen mRNA 
levels or procollagen protein synthesis. In cell layers TNF-a diminished the levels of 
mature collagen cross-links, pyridinoline and deoxypyridinoline. mRNA expression 
for LOX, is down-regulated by TNF-a in a concentration and time dependent manner 
by up to 50%. The decrease was accompanied by a significant reduction of LOX 
protein levels and enzyme activity indicating that TNF-a inhibits the expression and 
activity of LOX in osteoblasts, thereby contributing to perturbed collagen cross-linking 
and accumulation. A more recent report (Rodriguez, Cv et a/., 2008) shows that TNF- 
a decreases LOX mRNA levels, transcriptional and enzymatic activity in endothelial 
cells in a dose and time dependent manner and that the TNF-a receptor is a 
determining factor on this downregulation.
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2. HYPOTHESIS
Among the many events that occur in atherosclerosis, TNF-a is a major pro- 
inflammatory cytokine that is expressed in this condition. However, little is known 
about the effect of this cytokine on the regulation of LOX and its isoforms in 
cardiovascular tissues. Therefore, we hypothesize that TNF-a increases extracellular 
matrix production by increasing LOX and its relatives via MAPKs dependant pathways 
in cardiovascular tissues. In addition, important biological activities have been 
recently attributed to the LOX-PP including tumor suppressor activity. LOX-PP works 
by inhibiting Ras-dependent signaling including ERK1/2 MAPK activation. For that 
reason, we hypothesize that LOX-PP may inhibit the TNF-a stimulated signaling 
pathways and could inhibit proliferation and/or migration of vascular smooth muscle 
cells.
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3 OBJECTIVES
The aims of this study were:
1. To investigate the regulation of LOX and its isoforms (LOXL1-4) in response to 
TNF-a in vascular smooth muscle cells and tissues by investigating LOX 
enzymatic activity, gene expression in vivo and in vitro, protein expression and 
MAPK signaling pathways.
2. To evaluate the effect of the LOX pro-peptide in vascular smooth muscle cells 
by studying different cellular outcomes including cell growth, proliferation, 
and migration, the signaling pathways involved and the inhibition of the 
expression of matrix metalloproteinase-9.
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4. MATERIALS AND METHODS
4.1 Reagents:
Dulbecco's modified Eagle's medium (DMEM), penicillin-streptomycin solution, 
nonessential amino acids, trypsin-EDTA solution, phosphate-buffered saline, sodium 
pyruvate and NanoOrange® protein quantitation kit were purchased from Invitrogen 
(Carlsbad, CA, USA). Fetal bovine serum (FBS), bovine serum albumin (BSA) 7.5%, 
trypan blue, crystal violet and trichloroacetic acid were from Sigma (St. Louis, MO, 
USA). [3H]thymidine was from Perkin Elmer (Waltham, MA). TNF-a was from 
Peprotech (Rocky Hill, NJ, USA). RNeasy mini-RNA purification kits were purchased 
from Qiagen (Valencia, CA, USA). TaqMan probes, reverse transcription reagents 
and instruments for real time PCR were obtained from Applied Biosystems (Foster 
City, CA, USA). ERK1/2 inhibitor U0126, rabbit anti-MAPK antibodies against 
phospho-SAPK/JNK (Thr-183, Tyr-184); total SAPK/JNK, phospho-ERK1/2 (p44/42) 
(Thr-202, Tyr-204), total ERK1/2, phospho-p38 (Thr-180, Tyr-182), total p38 
antibodies, and secondary anti-rabbit horseradish peroxidase-conjugated antibodies 
were obtained from Cell Signaling (Danvers, MA, USA). MAPK pathway inhibitors SB 
203580 for P38 and JNK Inhibitor II SP600125 were from Calbiochem (San Diego, 
CA, USA). StrataClean™ Resin was obtained from Stratagene (La Jolla, CA, USA).
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4.2 Cell Culture:
Primary rat aorta smooth muscle cells (SMC) were isolated from 2 day old rat pups as 
described (Oakes, B.W., et a/., 1982), and were cultured in Dulbecco's Modified 
Eagles Medium supplemented with 10% fetal bovine serum, with 250 U/ml penicillin, 
and 250 pg/ml streptomycin, 0.1 mM non-essential amino acids, and 1 mM sodium 
pyruvate. Cells were incubated at 37°C under 5% C 0 2 in a fully humidified incubator. 
Cells were utilized after passage 1 under conditions described for each experiment. 
Cells at 80% to 90% confluence were made quiescent by incubation for 24 hours in 
serum free DMEM containing 0.1 % BSA.
4.3 Lysyl Oxidase Activity Assay:
Cells were plated and grown to 80% visual confluence. Phenol red-free and serum- 
free DMEM containing 0.1% BSA, was added for 24 h. Cells then were re-fed with 
fresh medium plus or minus TNF-a for 24 h. Lysyl oxidase enzyme activity was 
measured in the conditioned medium by a fluorometric assay. In this assay, LOX 
oxidatively deaminates diaminopentane generating hydrogen peroxide. Elorseradish 
peroxidase-catalyzed oxidation of /V-acetyl-3,7-dihydroxyphenoxazine (Amplex Red) 
by hydrogen peroxide produces fluorescent resorufin, which was measured using a 
Hitachi F-2000 fluorescence spectrometer with excitation and emission wavelengths
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at 563 and 587 nm, respectively. Parallel assays were prepared with 500 pM p- 
aminoproprionitrile fumarate to completely inhibit the activity of LOX, and the 
difference in emission intensity was recorded. The amount of hydrogen peroxide 
produced by the action of LOX was determined by comparing fluorescence changes 
to a standard plot relating fluorescence change to nanomoles of hydrogen peroxide 
(Palamakumbura, A.H., et a/., 2002).
4.4 RNA isolation and Real time PCR:
Total RNA was isolated from SMC cell cultures or 10 week old mouse aorta tissues 
and purified using RNeasy mini-RNA purification kits (Qiagen). Briefly, culture media 
was aspirated completely from culture plates, cells were disrupted by addition of 
buffer RLT and the monolayer was collected with the help of a cell lifter (Costar). The 
cell lysate was pipetted directly into a Qiashredder spin column, placed in a 
collection tube and centrifuged at full speed for 2 min. One volume of 70% ethanol 
was added to the homogenized lysate and mixed by pipetting. Then the sample was 
transferred into an RNeasy spin column for RNA binding, followed by washing with 
buffer RW1 and buffer RPE. Bound RNA was eluted in RNase-free water. RNA 
samples were then stored at -80°C. For the mouse tissues, aortic arch or the full aorta
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were stored in RNAlater stabilization reagent (Qiagen) and total RNA from 
approximately 30 mg of tissue was extracted following the manufacturers instructions.
RNA obtained was run on a 1% agarose gel to ensure RNA quality by analyzing for 
the presence of 18S and 28S rRNA in proper relative proportions. RNA was 
quantified via spectrophotometry (NanoDrop, Thermo Fisher Scientific, Pittsburgh, 
PA, USA) and 1 pg of RNA per treatment condition was added to 30 pI of reverse 
transcription reactions (IxRT buffer, 5.5 mM MgCI2, 500 pM per dNTP, 2.5 pM 
random Hexamers, 0.4 U/pl RNase inhibitor and 3.125 U/pl MultiScribe reverse 
transcriptase) using the Applied Biosystems Reverse Transcription kit. The reverse 
transcription thermal cycling conditions are: 25°C 10 min, 37°C for 60 min and 95°C 
for 5 min, followed by 4°C on hold. cDNA was stored at -20 °C prior to use in real 
time PCR. Two microliters of each reverse transcription reaction were used for 25 pi 
of real time PCR reaction (12.5 pi of Taqman Universal PCR master mix, 1.25 pi 
specific primer and 2 pi of template) using the traditional 96-well format. TaqMan 
probes for LOX, LOXL1, LOXL2, LOXL3, LOXL4, MMP9 and glyceraldehyde-3- 
phosphate dehydrogenase (GAPDH) were used in real time PCR analyses. Real time 
PCR were run in an Applied Biosystems GeneAmp Prism 7700 System at thermal 
cycler conditions of 50 °C for 2 min, 95 °C for 10 min, and 60 °C for 1 min for 40 
cycles. Data were analyzed using the 2‘AAct method (Livak, K.J., et a/., 2001) and 
mRNA levels were normalized to glyceraldehyde-3-phosphate dehydrogenase mRNA
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and no treatment controls. Briefly, threshold cycle CT values are defined as the cycle 
number at which the fluorescence exceeds the chosen threshold and are provided 
from the real-time PCR instrumentation. AACT = (CT target gene- CT endogenous 
control gene) sample- (CT target gene- CT endogenous control gene) calibrator. The 
fold change in the target gene, normalized to endogenous control and relative to the 
expression of the calibrator sample, was calculated by 2'AAcl.
4.5 MAP Kinase phosphorylation assay and Western Blot:
Growth arrested SMC were treated with 20 ng/ml TNF-a with or without 10 pg/ml 
LOX propeptide for the specified time periods at 37°C. Cell lysates were prepared 
with ice-cold lysis buffer (containing 50 mM Tris-CI pH 7.5 , 100 mM NaCI, 5 mM 
EDTA, 1% Triton-X-100, PMSF 0.5 mM, DTT 1 mM, PNPP 10 mM, NaF 10 mM, p- 
glycerophosphate 10 mM, protease inhibitor and phosphatase inhibitor). Samples 
were then subjected to 10% SDS-PAGE and Western blotting with antibodies specific 
for proteins of interest. Proteins were transferred to PVDF membranes overnight at 4 
°C in blotting buffer containing 0.025 M Tris, 0.192 M glycine, and 20% methanol. 
Membranes were blocked with blocking solution containing 5% dry milk in TBST (20 
mM Tris-HCl, pH 7.5, 150 mM NaCI, and 0.1% Tween) for 1 h in the presence of 
primary rabbit antibodies overnight at 4 °C with mild shaking. Membranes were then
52
washed with TBST 3 times for 10 min each. Membranes were next subjected to 
incubation in the presence of secondary, anti-rabbit horseradish peroxidase- 
conjugated antibodies in 5% powdered milk and TBST for 1 h at room temperature 
with mild shaking. Membranes were washed with TBST 3 times for 10 min each. 
Chemiluminescent detection of bound horseradish peroxidase-conjugated secondary 
antibodies was determined using the ECL Western Blotting Detection Reagents (GE 
Healthcare) and exposed to film. Membranes were subsequently stripped using 
Restore Western Stripping Solution (Pierce, Biotechnology, Rockford, IL)) and re­
probed for loading controls as required.
4.6 Cell growth assay:
SMC were grown in 12-well plates to 60% visual confluence and then placed in 
media containing 0.2% serum for 24 h. Cells were treated with fresh 0.2% serum- 
containing medium in the presence or absence of LOX-PP (lOpg/ml) alone, or 
vehicle alone (control). Cells were collected after 48 h by treatment with 
trypsin/EDTA and centrifugation at lOOOg. Cells were suspended in 50 pi DMEM and 
stained with 0.2% trypan blue, and viable cells were counted using a hemocytometer.
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4.7 DNA synthesis assay:
Cells were subcultured into 12-well plates and allowed to grow for 4 days to near 
visual confluency in DMEM containing 10% serum. Thereafter the cells were growth 
arrested in serum free medium containing 0.1% bovine serum albumin for 24 hours. 
Cells were pretreated with the LOX-PP for 2.5 hrs before the treatment with TNF-a 
(20 ng/ml) for 24 hours. Cells were then labeled with 2pCi/ml [ !H]-thymidine for 18 
hours. The experiments were terminated by washing the cells with ice cold PBS, 
precipitation with 10% TCA and extraction of the DNA with 0.2N NaOH and 0.1% 
SDS. Radioactivity was measured by liquid scintillation counting (Packard, Canberra 
Packard, Meriden, CT, USA).
4.8 Gelatin zymography assay:
Growth arrested SMC were treated with 20 ng/ml TNF-a with or without 10 pg/ml 
FOX propeptide for 24 hours at 37°C. Cells were collected and mixed with 2X non­
reducing sample buffer (0.5 m Tris-HCl, pH 6.8, 20% glycerol, 0.2% SDS, 0.0005% 
Bromophenol Blue) and electrophoresed on 0.75-mm-thick 8% sodium dodecyl 
sulphate-polyacrylamide gel elecrophoresis (SDS-PAGE) containing 0.1% gelatin as a 
protease substrate. Following electrophoresis, gels were washed in 2.5% Triton X-100, 
50 mm Tris-HCl, pH 7.5, for 1 h to remove SDS and then washed with 50 mm Tris-
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HCI, pH 7.5. Subsequently, gels were incubated for 20 h at 37°C in renaturation 
buffer (50 mm Tris-HCl, pH 7.5, 1 mm CaCl2 and 1 mm ZnCI2) on a rotary shaker. 
Afterwards, gels were stained in 30% methanol, 10% acetic acid and 0.2% (w/v) 
Coomassie Brilliant Blue for 1 h, followed by destaining in 30% methanol and 10% 
acetic acid. Gelatinolytic activity was manifested as horizontal white bands on a dark 
blue background.
4.9 Cell migration assay:
A migration assay was performed using the 12-well transwell insert membranes 
system (Costar), with 8 pm pore size polycarbonate filters. A step of initial equilibrium 
for the insert membrane was carried out by adding DMEM overnight at 37°C to the 
multiwell plate and then to the insert in order to improve cell attachment. Cells were 
grown in 10 cm diameter plates until they reached 80% - 90% confluence in DMEM 
containing 10% serum. Thereafter the cells were made quiescent in serum free 
medium containing 0.1% bovine serum albumin for 24 hours. Cells were trypsinized, 
washed twice with PBS and resuspended in serum free DMEM at a concentration of 
1 x 10s cells in 100 pi. TNF-a 20 ng/ml or 100 ng/ml, LOX-PP 5 pg/ml or 10 pg/ml or 
medium alone were added to the lower wells and the polycarbonate membrane was 
placed over those wells. The cell suspension was added to the upper wells in 100 pi 
aliquots. For inhibition of the MAPK experiments, inhibitors and LOX-PP were added
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to the cell suspension 2 hours before addition of the cells to the upper wells. The 
plates were incubated at 37 °C for 4 hours, and the membrane was then removed. 
The cells on the upper side of the membrane were removed by scraping with a 
cotton swab and cells on the lower face were fixed with 100% methanol and stained 
with 0.2% crystal violet in 10% ethanol. The number of migrated cells on the lower 
face of the filters was counted in the entire membrane under X4 magnification.
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5. RESULTS
5.1 PART I:
REGULATION OF LYSYL OXIDASE AND ITS RELATIVES BY TNF-a IN VASCULAR 
SMOOTH MUSCLE CELLS AND TISSUES:
5.1.1 LOX and LOXL2 are upregulated in vascular injury.
Preliminary studies from our lab had evaluated the presence in vivo of LOX and its 
isoforms on murine femoral arteries injured by guidewire scraping of the luminal 
surface and in sham operated control animals two weeks after injury. Data in Figure 
5A shows abundant expression of LOX in injured femoral arteries around the intima 
and the media layers, and little or no staining in uninjured arteries. Figure 5B shows 
expression of LOXL2 in injured femoral arteries when compared to the expression on 
the non injured vascular tissue. Based on these experiments, we wanted to evaluate 
the TNF-a regulation of LOX and its isoforms.
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LOX and LOXL2 are differentially regulated in vascular injury.
Figure 5:
A
Wild Type Wild Type Wild Type
Sham 400X Injured 400X Injured 1000X
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LOX and LOXL2 are differentially regulated in vascular injury.
A. LOX is expressed at elevated levels in the mouse with injured femoral arteries. 
Measure bar = 50 pm; photographed at 400x or lOOOx as indicated. Data are 
representative of three animals per group assayed. Primary antibody concentration = 
5 pg/ml.
B. LOXL2 is expressed at elevated levels in the wild type mouse with injured femoral 
arteries. Measure bar = 50 pm; photographed at 400x or lOOOx as indicated. Data 
are representative of three animals per group assayed. Primary antibody 
concentration = 10 pg/ml.
Figure 5:
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5.1.2 TNF-a increases lysyl oxidase enzyme activity in SMC.
It has been reported that TNF-a is a cytokine secreted by SMC in the neointima after 
balloon injury as well as by macrophages in atherosclerotic lesions (Tipping, P.G., et 
al., 1993), but little is known about the effect of this cytokine on LOX and its relatives 
in the context of atherosclerosis. For that purpose, based on the previous result that 
LOX is upregulated in vascular injury, we asked the question whether this up- 
regulation is due to TNF-a induced action on LOX. An experiment using Amplex 
Red, a fluorescent assay to measure the presence of LOX activity in media samples 
(Palamakumbura, A.H., et al., 2002), was designed. SMC were grown in serum and 
phenol red free medium for 24 hours in the presence or absence of 20 ng/ml of TNF- 
a. Lysyl oxidase enzyme activity was measured in the conditioned medium 
fluorometrically. Another set of samples was taken and 500 pM |3-aminoproprionitrile 
fumarate were added to inhibit the activity of LOX and the difference on emission 
between samples treated with p-APN and samples not treated was recorded. Figure 6 
shows that TNF-a increased LOX activity by 8.3 fold. Values for enzyme activity are 
the averages of 3 independent samples (*, p<0.05 versus control, using unpaired 
Students t-test assuming equal variances).
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Figure 6:
TNF-a increases lysyl oxidase enzyme activity in SMC.
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Enzyme activity was measured in the media samples from cells grown in serum- and 
phenol red-free media for 24 h in the presence of TNF-a 20 ng/ml. Values for 
enzyme activity are the averages of 3 independent samples. (*, p < 0.05 versus 
control using an unpaired Student's t test assuming equal variances).
Figure 6:
TNF-a increases lysyl oxidase enzyme activity in SMC.
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5.1.3 TNF-a increases LOXL2 and LOXL4 mRNA levels in neonate and adult rat
aortic SMC Fi^iFre5and LOXL3 and LOXL4 FiguFu.
We next wanted to evaluate whether TNF-a regulates LOX expression. To achieve 
this objective, an in vitro experiment was designed. SMC were treated in serum-free 
DMEM supplemented with 0.1% BSA in the absence or presence of various 
concentrations of TNF-a for 24 hours. Total RNA was isolated and subjected to Real 
Time PCR. The purpose of the first experiment was to determine the optimal 
concentration of TNF-a to use throughout our studies. Results in Figure 7A show a 
significant increase in LOXL2 and LOXL4 that is dependant on the concentration of 
TNF-a, therefore we decided to use the highest concentration in accordance to 
widely published reports. Surprisingly, our results shown in Figure 7B indicate that 
treatment of SMC with TNF-a does not have any significant effect on LOX mRNA 
levels. For that reason, we decided to explore further and evaluate if TNF-a regulates 
instead some of the other LOX isoforms. The RNA samples were subjected to Real 
Time PCR and the results show a significant increase in steady-state levels of LOXL2 
and LOXL4 (Figure 7B). Similar results were observed in adult SMCs (Figure 7C). 
Although LOXL1 also shows a significant increase, this up-regulation is very weak. 
Taken together, these data suggests that the increased LOX enzymatic activity is likely 
caused by the up-regulation of LOXL2 and LOXL4 but not LOX itself and there are no
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significant differences between adult and neonate SMC. Data on Figure 7B are the 
averages of 6 independent experiments (*, p < 0.05; **, p < 0.005; #, p < 0.0005). 
Data on Figure 7C are the averages of 3 independent samples (*, p < 0.05; **, p <
0.0005).
Along those lines, we wanted to corroborate our previous results in vivo. For that 
purpose, we injected intraperitonealy 10 week old mice with 150 pg/kg TNF-a or 
PBS for 16 hours. Mice were sacrificed, tissues dissected and total RNA extracted. 
Figure 7C and Figure 7D show that LOX, LOXL3 and LOXL4 were significantly 
increased in the aortic arch, whereas in the full aorta (Figure 7E) only LOXL3 and 
LOXL4 were significantly increased. LOXL1 was not detected in any of the aortic 
tissues. This data present some discrepancy with the in vitro data, since our findings 
show that LOX and LOXL3 are not regulated in the cell culture while in vivo TNF-a 
up-regulates LOX and LOXL3. Data from full aorta indicate that LOXL3 is up- 
regulated in vivo but not in vitro, whereas LOXL4 is consistently up-regulated in both 
cases. The values shown are the result of 6 different mice (*, p<0.005).
64
Figure 7:
TNF-a increases LOXL2 and LOXL4 mRNA levels in neonate and adult rat aortic 
SMC FiguFe 7and LOXL3 and LOXL4 FiguFu.
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TNF-a increases LOXL2 and LOXL4 mRNA levels in neonate and adult rat aortic 
SMC FiguFe 7and LOXL3 and LOXL4 FiguFu.
A. Rat aortic SMC cultured and serum starved for 24h, were then treated with or 
without TNF-a (0.5 ng/ml, 2 ng/ml and 20 ng/ml) for 24h. Total RNA was isolated 
and subjected to Real Time PCR. LOXs mRNA expression was normalized to 
glyceraldehyde-3-phosphate dehydrogenase mRNA and compared with no treatment 
control cultures. The values shown are the averages of 3 independent samples (*, p <
0.05; * * ,p  < 0.005).
Figure 7:
B. Rat aortic SMC cultured and serum starved for 24h, were then treated with or 
without TNF-a for 24h. Total RNA was isolated and subjected to Real Time PCR. 
LOXs mRNA expression was normalized to glyceraldehyde-3-phosphate 
dehydrogenase mRNA and compared with no treatment control cultures. The values 
shown are the averages of 6 independent experiments (*, p < 0.05; **, p < 0.005; 
# ,p  < 0.0005).
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C. Adult Rat aortic SMC cultured and serum starved for 24h, were then treated with 
or without 20 ng/ml of TNF-a for 24h. Total RNA was isolated and subjected to Real 
Time PCR. LOXs mRNA expression was normalized to glyceraldehyde-3-phosphate 
dehydrogenase mRNA and compared with no treatment control cultures. The values 
shown are the averages of 3 independent samples (*, p < 0.05; **, p < 0.0005).
D. 10 Week old mice injected intraperitonealy with 150 pg/kg TNF-a or PBS for 16 
hours were sacrificed. Aortic arch was dissected and stored in RNAlater. Total RNA 
was isolated and subjected to Real Time PCR. LOXs mRNA expression was 
normalized to glyceraldehyde-3-phosphate dehydrogenase mRNA and compared 
with PBS samples. The values shown are the result of 6 different mice (*, p <0.005)
E. 10 Week old mice injected intraperitonealy with 150 pg/kg TNF-a or PBS for 16 
hours were sacrificed. Full aortas were dissected and stored in RNAlater. Total RNA 
was isolated and subjected to Real Time PCR. LOXs mRNA expression was 
normalized to glyceraldehyde-3-phosphate dehydrogenase mRNA and compared 
with PBS samples. The values shown are the result of 6 different mice (*, p<0.005; 
**, p<0.05).
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5.1.4 TNF-a increases LOX protein expression in organ cultures.
To explore the previous results further, we wanted to investigate whether TNF-a 
regulates LOX protein expression in organ cultures. It is already stated that LOX is 
increased in atherosclerosis (Kagan, H.M., et a/., 1981) but little is known about the 
TNF-a regulation of LOX in aortic tissues. To address this issue, aortic rings without 
adventitia from 10 week old mice were cultured in DMEM and treated with or 
without 20 ng/ml or 100 ng/ml of TNF-a for 24 hours. Conditioned media were 
collected and proteins were concentrated with StrataClean™ resin. Briefly, protein 
concentrations were determined by the NanoOrange® protein quantitation kit 
following the manufacturer's instructions. 10 pi of StrataClean™ resin were added to 
100 ng/ml of protein, samples were vortex-mixed for 30 min at 4°C to allow binding 
of the proteins to the resin and centrifuged. The supernatant was removed and the 
pelleted resin was mixed with sample buffer and loaded onto an SDS-PAGE protein 
gel followed by immunoblotting. Our findings shown in Figure 8 demonstrate that 
both concentrations of TNF-a up-regulate LOX in a significant manner [data shown 
corresponds to 3 different mice. (*, p<0.05; **, p<0.005)[. Taken together, these 
data suggest that TNF-a up-regulation of LOX in aortic tissues may occur 
independent of SMC. Table 1 summarizes the effects of TNF-a in LOX and its 
isoforms and the differences present in different study models.
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Figure 8:
TNF-a increases LOX protein expression in aortic organ culture media.
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Aortic rings without adventitia from 10 week old mice were cultured in DMEM and 
treated with or without 20ng/ml or 100 ng/ml of TNF-a for 24 hours. Conditioned 
media were collected, protein quantification was made and diluted proteins were 
concentrated with StrataClean™ resin. Briefly, protein concentrations were 
determined by the NanoOrange® protein quantitation kit following the 
manufacturer's instructions. Protein-resin mixture was loaded onto an SDS-PAGE 
protein gel followed by LOX immunoblotting. Data shown corresponds to 3 different 
mice. (*, p < 0.05; **, p<0.005).
A. Densitometric analysis of AntiLOX/Total protein concentration in media aortic 
tissue culture is presented.
7
B. A representative Western blot is presented.
Figure 8:
TNF-a increases LOX protein expression in aortic organ culture media.
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Table 1.
Effect of TNF-a on lysyl oxidase and its isoforms in different study models.
Mouse tissues
Organ cultures In vitro results in 
cultured SMCs
Arch Aorta Arch Enzyme mRNA levels
activity
LOX t t t
LOXL1
LOXL2 t
LOXL3 t t
LOXL4 t t t
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Table 1.
Effect of TNF-a on lysyl oxidase and its isoforms in different study models.
The table summarizes the effects of TNF-a in LOX and its isoforms in different study 
models.
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5.1.5 TNF-a stimulates MAPK activation in SMC.
A following experiment was designed to determine if the MAPK signaling pathway is 
activated by TNF-a. For that purpose, cells were serum starved for 24 hours in 0.1% 
BSA medium. For MAPK activation, SMC were treated with or without two different 
concentrations of TNF-a (20 ng/ml and 100 ng/ml). SMC layer samples were 
subjected to Western Blot analysis with antibodies against P-ERK1/2, P-P38 and P- 
JNK1/2. Figure 9 shows the results obtained demonstrating that TNF-a increases 
phosphorylation of all three MAPKs at a concentration of 20 ng/ml in a significant 
manner although activation of JNK was weak (ERK1/2, 5-fold.; P38, 13-fold, JNK1/2, 
2.5-fold). At a TNF-a concentration of 100 ng/ml the activation or ERK1/2 and P38 
was significantly higher (10-fold and 10.4-fold respectively) than untreated controls, 
however JNK was not activated.
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Figure 9:
TNF-a stimulates MAPK activation in Rat aortic SMC.
A.
TNF-a 20 ng/ml - +
TNF-a 100 ng/ml - - +
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T-ERK1/2
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TNF-a stimulates MAPK activation in SMC.
SMC were cultured and serum starved for 24 h. Different concentrations of TNF-a 
were added to the media for 10 min for ERK1/2 and p38 and 15 min for JNK, based 
on preliminary time studies (not shown). Cell layers were isolated and subjected to 
Western blotting using p-ERKI/2, p-p38 and p-JNK antibodies. Expression of Total 
ERK1/2, p38 and JNK were measured as internal controls. The values shown are the 
averages of 3 independent experiments. (*, p < 0.05; **, p <0.005T
A. Western blot of p-ERKAEotal ERK and densitometric analysis of p-ERK1/2/Total 
ERK1/2 protein expression in SMC is presented.
B. Western blot of p-p38/Total p38 and densitometric analysis of p-p38/Total p38 
protein expression in SMC is presented.
C. Western blot of p-JNK1/2/Total JNK and densitometric analysis of p-JNK1/2/Total 
JNK1/2 protein expression in SMC is presented.
Figure 9:
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5.1.6 The pharmacologic inhibitor of the ERK1/2 MAPK pathway is a weak 
inhibitor of TNF-a stimulated expression of LOXL2 and LOXL4:
In order to begin elucidating the pathway involved in the TNF-a up-regulation of 
LOXL2 and LOXL4, we evaluated the effect of the pharmacologic inhibitor of ERK1/2 
(U0126) on mRNA levels of LOX and its isoforms in SMC. Briefly, aortic smooth 
muscle cells were cultured and serum starved for 24 hours. For ERK1/2 inhibitor 
treatment, cells were pretreated for 1h with 10 pM U0126 and media were then 
replaced with fresh MAPK inhibitor and TNF-a (20 ng/ml). Total RNA was isolated 
and subjected to Real Time PCR. LOXs mRNA expression was normalized to 
glyceraldehyde-3-phosphate dehydrogenase mRNA and compared with no treatment 
control cultures. Figure 10 shows a small decrease of the LOXL2 (18%) and LOXL4 
(16%) mRNA levels in the presence of U0126 indicating that there are other 
pathways involved in LOX isoforms regulation by TNF-a. The values shown are the 
averages of 3 independent samples (*, p <0.05).
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Figure 10:
The pharmacologic inhibitor of the ERK1/2 MAPK pathway U0126 is a weak 
inhibitor of TNF-a stimulated expression of LOXL2 and LOXL4.
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Figure 10:
The pharmacologic inhibitor of the ERK1/2 MAPK pathway U0126 partially 
inhibits TNF-a stimulated expression of LOXL2 and LOXL4.
SMC were cultured and serum starved for 24 hours. For ERK1/2 inhibitor treatment, 
cells were pretreated for 1h with 10 pM U0126 and media was then replaced with 
fresh MAPK inhibitor and TNF-a (20 ng/ml). Then, the control groups were treated 
with or without TNF-a for another period of 24 hours. Total RNA was isolated and 
subjected to Real Time PCR. LOXs mRNA expression was normalized to 
glyceraldehyde-3-phosphate dehydrogenase mRNA and compared with no treatment 
control cultures. The values shown are the averages of 3 independent samples (*, p 
<0.05 ).
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5.2 PART II: LYSYL OXIDASE PROPEPTIDE (LOX-PP) INHIBITS TNF-a
STIMULATED ERK1/2 PHOSPHORYLATION, MMP-9 EXPRESSION, VASCULAR 
SMOOTH MUSCLE CELL PROLIFERATION AND MIGRATION:
Our previous results show that TNF-a induces the activation of ERK1/2, P38 and JNK, 
key transducers of extracellular signals that promote cell growth and movement, 
which are critical for the initiation and progression of vascular lesions. Little is known, 
however, about the effect of the LOX pro-peptide in this model.
5.2.1 LOX-PP inhibits SMC growth through ERK1/2 and p38 signaling pathway:
Pro-LOX, mature LOX, and therefore LOX-PP are expressed in vascular smooth 
muscle cells (Trackman, P.C., et a/., 1992). Here, we examined the potential of 
purified LOX-PP to influence SMC properties in order to explore possible novel 
experimental therapeutic strategies for vascular disease. The effect of LOX-PP on the 
growth of vascular SMCs was first determined. For this purpose, a cell growth assay 
was done. Briefly, rat aorta SMC were grown until 60% visual confluence was 
reached. Then, cells were starved in medium containing 0.2% serum in the presence 
or absence of LOX-PP (10 pg/ml) (concentration based on preliminary dose-response 
studies (Palamakumbura, A.H., et a/., 2004; Min, C., et a/., 2007; Wu, M v et a/., 
2007) for 48 hours. The number of viable cells was determined on day 2 by 0.2%
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trypan blue staining and cell counting using a hemocytometer. Figure 11A shows that 
LOX-PP significantly inhibits the growth of SMC cultures by a 57% (n = 3; *p, 
<  0 .0001).
In order to confirm this data, we next measured if LOX-PP inhibits DNA synthesis in 
vascular aortic smooth muscle cells. To prove this statement, Rat aortic SMC were 
cultured and serum starved for 24 hours. LOX-PP (5 or 10 pg/ml) or vehicle were 
added to cultures for 24 h. Cells were labeled with tritiated thymidine for 18 hours 
and incorporation was then determined by liquid scintillation counting. Figure 11B 
shows that LOX-PP inhibits significantly thymidine incorporation in SMC by a 92% for 
LOX-PP 5 pg/ml and 57% for LOX-PP 10 pg/ml. Values shown are the averages of 
three independent cultures (*p < 0.005; **p < 0.05).
Finally, to investigate further the signaling pathways involved in this process, we 
inhibited the MAPK signaling pathway with its specific pharmacologic inhibitors. It has 
been reported that rat aortic SMC DNA synthesis can be stimulated with 5% serum 
(Kim, T.J., et a/., 2007), so we used this stimulation as our positive control. Rat aortic 
SMC were cultured and serum starved for 24 hours. Next, cells were pretreated for 
24 hours with LOX-PP or with the pharmacological inhibitors U0126, SB 203580 and 
SP600125 for 1 hour. Then, cells were stimulated with 5% serum for 12 hours. Cells 
were then labeled with tritiated thymidine for 18 hours and incorporation was then
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measured by liquid scintillation counting. Our results shown on Figure 11C indicate 
that the LOX-PP inhibits serum-stimulated DNA synthesis of rat aortic SMC by a 40% 
and this inhibition is ERK1/2 and p38 dependant (inhibition of 56% and 40% 
respectively) and JNK seems not to be involved.
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Figure 11.
LOX-PP could inhibit growth of SMC in cultures through the ERK1/2 and/or p38 
signaling pathways.
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Figure 11.
LOX-PP could inhibit growth of SMC in cultures through the ERK1/2 and/or p38 
signaling pathways.
A. Primary neonatal rat aortic SMCs were grown as described in the presence of LOX- 
PP (10 pg/ml) or vehicle and the number of viable cells per culture determined on 
day 2. n =  3; *p < 0.0001).
B. Rat aortic SMCs were cultured and serum starved for 24 hours. LOX-PP (5 or 10 
pg/ml) or vehicle were added to cultures for 24 h. Cells were labeled with tritiated 
thymidine for 18 hours and incorporation was then determined by liquid scintillation 
counting. Values shown are the averages of three independent cultures (*p < 0.005; 
**p < 0.05).
C. Primary neonatal rat aortic SMCs were cultured and growth arrested for 24 hours 
in serum free medium. To evaluate the effect of MAPK inhibitors, cells were 
pretreated for 1h with 10 pM U0126, SB203580 and SP600125 and for 24 hours 
with LOX-PP. Then, in order to stimulate DNA synthesis and have a positive control, 
a group of cells was stimulated with 5% serum alone. The other cell groups were fed 
with 5% serum fresh media along with the LOX-PP and 3 different MAPK inhibitors
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respectively for 12 hours. Cells were labeled with tritiated thymidine for 18 hours and 
incorporation was then determined by liquid scintillation counting. Values shown are 
the averages of six independent cultures (*p < 0.05; **p < 0.005).
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5.2.2 LOX-PP inhibits TNF-a stimulated MMP-9 expression:
TNF-a up-regulates MMP-9 expression in human SMCs and this is mediated by 
ERK1/2 Map kinase activation (Moon, S.K., et a/., 2004). To begin our experiments, 
we decided to confirm this finding in rat vascular SMCs. For this purpose, rat aorta 
vascular smooth muscle cells were cultured and serum starved for 24 hours. For 
ERK1/2 inhibitor treatment, cells were pretreated for 1 hour with 10 pM U0126 and 
media were then replaced with fresh MAPK inhibitor and 20 ng/ml TNF-a. Total 
mRNA was isolated and subjected to Real Time PCR. MMP-9 was normalized to 
gyceraldehyde-3-phosphate dehydrogenase mRNA and compared with no treatment 
control cultures. Results on Figure 12 indicate the that TNF-a significantly up- 
regulates MMP-9 mRNA levels in rat aorta vascular smooth muscle cells by 40-fold, 
and the inhibition of this process by a 70% using the ERK1/2 inhibitor, confirms the 
involvement of this signaling pathway. The values shown are the averages of 3 
independent samples. (*, p<0.0005, **, p < 0.05).
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Figure 12.
TNF-a stimulates MMP-9 via ERK1/2 activation in SMC
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Rat aorta vascular smooth muscle cells were cultured and serum starved for 24 hours. 
For ERK1/2 inhibitor treatment, cells were pretreated for 1 hour with 10 pM U0126 
and media was then replaced with fresh MAPK inhibitor and TNF-a. Total mRNA was 
isolated and subjected to Real Time PCR. MMP-9 was normalized to gyceraldehyde- 
3-phosphate dehydrogenase mRNA and compared with no treatment control 
cultures. The values shown are the averages of 3 independent samples. (*, 
p<0.0005, **, p<0.05)
Figure 12.
TNF-a stimulates MMP-9 via ERK1/2 activation in SMC
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Based on this data, we can hypothesize that LOX-PP could inhibit TNF-a-stimulated 
MMP-9 production via ERK1/2. To test this, SMC were treated with 1 pg/ml or 
10 pg/ml LOX-PP or vehicle, followed by TNF-a for 24 hours. RNA was isolated and 
analyzed by qPCR. Figure 13 shows that both concentrations of LOX-PP reduce 
MMP-9 mRNA levels, with somewhat greater inhibition occurring at 10 pg/ml (30%).
Studies had reported that TNF-a can stimulate MMP-9 activity (Moon, S.K., et a/., 
2004; Cho, A., et a/., 2000; Kim, H.M., et a/., 2007; Ha, K.T., et a/., 2004; Jin, U.HV 
et a/., 2006; Lee, S.O., et a/., 2006; Kim, H.S., et a/., 2007; Li, H., et a/., 2007; 
Moon, S.K., et a/., 2003; Moon, S.K., et a/., 2007; Lee, C.W., et a/., 2007; Moon, 
S.K., et a/., 2004; Suh, S.J.„ et a/., 2006), therefore we were interested in determine if 
the LOX-PP could inhibit the effect on the enzymatic activity of MMP-9 in response 
to TNL-a. For that purpose we designed a zymography assay in which SMC were 
cultured and serum starved for 24 hours, and treated with TNF-a for another period 
of 24 hours. Then, cells were collected and mixed with a non-reducing sample buffer 
and electrophoresed on a gel containing gelatin as a protease substrate as described 
in materials and methods. Gels were then stained and gelatinolytic activity was 
manifested as horizontal white bands on a dark blue background. Unfortunately, we 
could not detect any MMP-9 activity in response to TNF-a or a combination of TNF-
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a and LOX-PP maybe because of the high activation by MMP-2 that makes very 
difficult to evaluate for presence of MMP-9 (Figure 14).
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Figure 13.
LOX-PP is a weak inhibitor of (A) TNF-a stimulated of MMP-9 mRNA levels.
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Primary neonatal rat aortic SMCs were treated with or without 20 ng/ml TNF-a in the 
presence and absence of LOX-PP for 24 hours. MMP-9 and GAPDF1 mRNA levels 
were determined by qPCR with Taqman reagents. Data are pooled from two different 
experiments with three independent cultures each, and are expressed as a per cent of 
TNF-a-stimulated MMP-9 mRNA levels ± SE, normalized to GAPDH. p < 0.05; 
"p < 0.004, n = 3.
Figure 13.
LOX-PP is a weak inhibitor of (A) TNF-a stimulated of MMP-9 mRNA levels.
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MMP-9 enzymatic activity
Figure 14.
TNF-a 20 ng/ml - + +
LOX-PP10 M-g/ml - - +
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MMP-9 enzymatic activity.
SMC were cultured and serum starved for 24 h. TNF-a was added to the media for 
24 hours. Cell layers were isolated and subjected to zymography. Bands correspond 
to 72 kDa (proMMP-2) and 64 kDa (active MMP-2). MMP-9 (92 kDa) could not be 
detected.
Figure 14.
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Next, we determined whether LOX-PP inhibits TNF-a stimulated MAPK pathway 
activation in SMC. Cells were treated with 10 pg/ml LOX-PP or vehicle for 24 hours, 
and then with TNF-a or vehicle for 10 or 15 min, based on preliminary time course 
studies (not shown). Figure 15A and 15B show that LOX-PP inhibits TNF-a-stimulated 
ERK1/2 activation at both concentrations of TNF-a (TNF-a concentration of 20 ng/ml 
was inhibited in a 58.2% and TNF-a concentration of 100 ng/ml was inhibited in a 
62.1%). LOX-PP had no significant effect on the basal level of phosphorylated ERK1/2 
(data not shown). Figure 15C and 15D indicate the effect of LOX-PP on p38 
activation. Our results show that LOX-PP inhibits TNF-a stimulated p38 
phosphorylation at a concentration of 20 ng/ml in a 37% in a significant manner; 
however at a concentration of 100 ng/ml, this inhibition was not significant. Figure 
15Eand 15Fshow no effect of the LOX-PP on JNK1/2 phosphorylation in response to 
TNF-a.
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LOX-PP inhibits ERK1/2 activation, (A, B); P38 activation (C, D) and JNK activation
Figure 15.
(E, F).
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LOX-PP inhibits ERK1/2 activation, (A, B); P38 activation (C, D) and JNK activation 
(E, F).
A. Primary neonatal rat aortic SMCs were cultured for 24 h in the presence or 
absence of 10 pg/ml LOX-PP or vehicle. Cells were then stimulated with 20 ng/ml or 
100 ng/ml TNF-a or vehicle (PBS) for 10 min. Cells were extracted and aliquots 
subjected to Western blotting for phosphorylated, and total ERK1/2, respectively. 
Graph shows densitometric quantitation of phosphorylated ERK1/2 levels normalized 
to total ERK1/2. (*p < 0.05; **p <0.006; ***p <0.0004)
B. Contains a representative Western blot.
C. Primary neonatal rat aortic SMCs were cultured for 24 h in the presence or 
absence of 10 pg/ml LOX-PP or vehicle. Cells were then stimulated with 20 ng/ml or 
100 ng/ml TNF-a or vehicle (PBS) for 10 min. Cells were extracted and aliquots 
subjected to Western blotting for phosphorylated, and total p38, respectively. Graph 
shows densitometric quantitation of phosphorylated p38 levels normalized to total 
p38. (*p < 0.005; **p <0.05)
D. Contains a representative Western blot.
Figure 15.
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E. Primary neonatal rat aortic SMCs were cultured for 24 h in the presence or 
absence of 10 pg/ml LOX-PP or vehicle. Cells were then stimulated with 20 ng/ml or 
100 ng/ml TNF-a or vehicle (PBS) for 15 min. Cells were extracted and aliquots 
subjected to Western blotting for phosphorylated, and total JNK1/2, respectively. 
Graph shows densitometric quantitation of phosphorylated JNK1/2 levels normalized 
to total JNK1/2. (*p < 0.0005).
F. Contains a representative Western blot.
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5.2.3 LOX-PP inhibits SMC migration through MAPK signaling pathways:
The proinflammatory cytokine TNF-a is considered to play a key role in the induction 
of smooth muscle cell proliferation and migration (Rajesh, M., et al., 2008; Tedgui, 
A., et al., 2006). Initially, we wanted to determine if LOX-PP could inhibit the TNF-a 
induced proliferation of SMC. For that purpose, a thymidine incorporation 
experiment was designed. Cells were cultured and serum starved for 24 hours. Two 
different concentrations of TNF-a (20 ng/ml and 100 ng/ml) or vehicle were added to 
cultures for 24 h. Cells were labeled with tritiated thymidine for 18 hours and 
incorporation was then determined by liquid scintillation counting. Unfortunately, 
several repetitions of our experiments always yielded a decrease in cell proliferation 
of a 70%, therefore we could not confirm those findings (explained on Figure 16).
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Figure 16:
TNF-a inhibits SMC DNA synthesis.
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Rat aortic SMCs were cultured and serum starved for 24 hours. TNF-a (20 or 100 
ng/ml) or vehicle was added to cultures for various timepoints (not shown) and 
24 hours. Cells were labeled with tritiated thymidine for 18 hours and incorporation 
was then determined by liquid scintillation counting. Values shown are the averages 
of three independent experiments (*p < 0.05).
Figure 16:
TNF-a inhibits SMC DNA synthesis.
107
Based on this result, we decided to examine whether TNF-a stimulated migration of 
rat aortic SMC was decreased by LOX-PP and whether this process is dependant on 
the MAPK signaling pathways. A migration assay was carried out with 5 and 10 pg/ml 
of LOX-PP in the presence of TNF-a (20 and 100 ng/ml). SMC were serum starved 
for 24 hours. Cells were trypsinized and incubated for 2 hours with LOX-PP or MAPK 
inhibitors (U0126, SB203580 and SP600125) respectively, then they were seeded on 
transwell membranes to allow migration towards chemoattractans TNF-a, LOX-PP or 
untreated controls. After 4 hours incubation, cells on the bottom side of the transwell 
membrane were fixed, stained and counted. (*, p<0.05). Results shown in Figure 14 
indicate that migration of rat aortic SMC was increased by treatment with TNF-a in a 
67% for the TNF-a concentration of 20 ng/ml; and a 71% for the TNF-a 
concentration of 100 ng/ml when compared with untreated control cells. LOX-PP 
inhibits TNF-a stimulated migration at both, 5 pg/ml and 10 pg/ml in a 62% and 60% 
respectively for the TNF-a concentration of 20 ng/ml and 64% and 71% at a TNF-a 
concentration of 100 ng/ml.
Likewise, all MAPK pharmacologic inhibitors also decreased the TNF-a stimulation of 
migration in SMC at both concentrations of TNF-a in a 58%-71%.
Table 2 summarizes the principal biological effects of LOX-PP in SMCs.
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A migration assay was carried out with 5 and 10 pg/ml of LOX-PP in the presence of 
TNF-a (20 and 100 ng/ml). SMC were serum starved for 24 hours. Cells were 
trypsinized and incubated for 2 hours with LOX-PP or MAPK inhibitors (U0126, 
SB203580 and SP600125) respectively, then they were seeded on transwell 
membranes to allow migration towards chemoattractans TNF-a, LOX-PP or untreated 
controls. After 4 hours incubation, cells on the bottom side of the transwell 
membrane were fixed, stained and counted. (*, p < 0.05).
Figure 17:
LOX-PP inhibits SMC migration through MAPK signaling pathways.
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Table 2.
Principal biological effects of LOX-PP in cultured SMCs.
No Serum TNF-cc
treatment Stimulation stimulation
Cell growth
DNA synthesis 1
MMP-9 mRNA levels Weak i
MAPK activation ERK1/2 I
P38 I
JNK1/2
Migration I
I l l
Table 2.
Principal biological effects of LOX-PP in SMCs.
The table summarizes the principal biological effects of LOX-PP in SMC.
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5.2.4 LOX-PP does not affect the TNF-a stimulation of LOXL2 and LOXL4.
Recent studies have shown that LOX-PP inhibits ERK1/2 phosphorylation (Min, Cv et 
a/., 2007; Wu, M v et a/., 2007). Our results shown in Figure 13 indicate that a weak 
inhibition of the TNF-a stimulation of FOXF2 and FOXF4 is achieved by treating SMC 
with the pharmacological inhibitor of the ERK1/2 pathway. Therefore, we wanted to 
evaluate the effect of the FOX-PP in the TNF-a stimulation of FOXF2 and FOXF4. For 
that purpose, SMC were serum starved with DMEM supplemented with 0.1% BSA in 
the absence or presence of FOX-PP 10 pg/ml for 24 hours. Cells were then treated 
with 20 ng/ml TNF-a. Total RNA was isolated and subjected to Real Time PCR. 
Expression of FOX and its relatives were normalized to gyceraldehyde-3-phosphate 
dehydrogenase mRNA and compared with no treatment control cultures. 
Interestingly, our results on Figure 18 show that TNF-a does not have any significant 
effect on FOX mRNA levels.
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Figure 18:
LOX-PP does not affect the TNF-a mRNA stimulation of LOXL2 and LOXL4.
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Primary neonatal rat aortic SMCs were treated with or without 20 ng/ml TNF-a in the 
presence and absence of LOX-PP for 24 hours. LOXs and GAPDFI mRNA levels were 
determined by qPCR with Taqman reagents. Data are the result from three different 
cultures.
Figure 18:
LOX-PP does not affect the TNF-a mRNA stimulation of LOXL2 and LOXL4.
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6. DISCUSSION
Atherosclerosis is a progressive disease characterized by accumulation of lipids and 
fibrous elements in arteries. From the cellular point of view, it is characterized by 
monocyte infiltration into the subendothelial space. A great variety of 
proinflammatory cytokines have been shown to be expressed in atherosclerotic 
lesions, especially in association with infiltrating monocytes and macrophages (Ross, 
R., 1993). TNF-a is a proinflammatory cytokine that has been shown to have 
important effects on various cell types that are components of atherosclerotic lesions. 
TNF-a is produced by macrophages, endothelial cells and smooth muscle cells and 
fibroblasts in atherosclerotic arteries (Beutler, B., et a/., 1986; Clausell, Nv et al., 
1995; Tipping, P.G., et a/., 1993; Barath, et a/., 1990).
LOX is a critical enzyme for the normal biosynthesis of extracellular matrix: collagen 
and elastin, which could suggest a possible role in cardiovascular diseases. Recently, 
four novel lysyl oxidase-like enzymes have been described, LOXL1, LOXL2, LOXL3 
and LOXL4. LOX and LOXL enzymes seem to be multifunctional but many of these 
functions remain to be elucidated, especially in atherosclerosis.
116
The first part of our study focuses on the TNF-a regulation of LOX and its isoforms. 
Not many studies have explored the connection between LOX and TNF-a. One of 
the first investigations was made in our lab and shows that in the presence of TNF-a, 
there is less accumulation of collagen in the extracellular matrix of osteoblast cultures, 
and that the deposited collagen contains diminished levels of mature collagen cross­
links. Those effects were caused partly by a down-regulation of LOX expression and 
activity by TNF-a suggesting a possible mechanism that could contribute to 
diminished osteoblast function, bone remodeling and bone resorption (Pischon, N., 
et a/., 2004). Based on this, and the importance of TNF-a in vascular disease, we 
questioned whether TNF-a has an effect on LOX in cardiovascular disease. Our 
preliminary results by immunohistochemistry suggest that LOX and LOXL2 expression 
is increased in mouse injured femoral arteries when compared to sham operated 
control animals two weeks after guidewire injury. In order to further investigate this, 
we decided to evaluate the effects of TNF-a on LOX in cultured vascular SMC since 
they are the most important cells in the process of atherosclerosis and are the major 
producers of extracellular matrix within the vessel wall. SMC can also react to 
vascular injury faster by increasing their proliferation and migration altering the 
surrounding ECM. Therefore, cultured SMC serve as a good model to evaluate the 
effects of TNF-a.
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Our first approach was to investigate whether LOX enzyme activity was affected by 
TNF-a. Based on the previous studies on osteoblast cells (Pischon, N., et a/., 2004), 
we expected that LOX activity would be reduced by TNF-a treatment. Surprisingly, 
we observed about a 5-fold increase in LOX activity by 20 ng/ml TNF-a in SMC. 
However LOX mRNA levels were not affected by the same concentration of TNF-a or 
by higher concentrations. Interestingly, LOXL2 and LOXL4 mRNA levels were 
increased by TNF-a suggesting that some of the functions that were currently 
attributed to a single enzyme may be because of different LOX-like proteins or a 
combination of them. It has been reported that LOXL2 and LOXL4 show enzyme 
activity similar to LOX and both enzymes can be inhibited by |3-APN (Ito, H., et a/., 
2001).
In vivo studies presented here with TNF-a injected mice showed an increase of 
mRNA levels of LOXL3 and LOXL4 in contrast to in vitro studies showing increases in 
LOXL2 and LOXL4. The increase in LOXL4 mRNA levels is expected because of the 
increase in LOX activity, however the function of LOXL3 is not known. In addition, 
LOX protein expression was increased in TNF-a treated organ cultures. There are 
several possible reasons for observing different outcomes between in vitro smooth
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muscle cell cultures and in vivo studies.
Intercellular interactions could be one reason for these differences. It has been
reported that TNF-a disturbs the endothelial integrity and induces leukocyte 
adhesion molecules and proinflammatory cytokines (Wang, P., et a/., 1994). 
Moreover, LOX expression and activity were declined in presence of low density 
lipoprotein (LDL) increasing endothelial permeability (Rodriguez, C., et al., 2002). 
Therfore, the decreased LOX levels found in endothelial cells could be associated 
with alterations in endothelial ECM allowing the movement of molecules through the 
endothelial layer affecting the neighboring smooth muscle cells suggesting an 
important role in atherosclerosis. Similarly, another study by Rodriguez, et al., found 
that LOX levels were declined by treatment with TNF-a in endothelial cells. 
However, this effect was caused by very low concentrations of TNF-a (0.5-1 ng/ml) 
(Rodriguez, Cv et al., 2008). We find this is difficult to understand because effective 
concentrations of TNF-a are reported to be between 10 to 100 ng/ml. Taken 
together, these results suggest that within the blood vessel, different cell types can 
elicit different effects that cannot be detected in in vitro models, those can only 
approximate conditions.
The age of the mouse could be another factor for the difference between in vivo and 
in vitro studies since we have used neonatal cells for our in vitro experiments.
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However, our results show that the effect of TNF-a on mRNA expression in adult 
SMC cultures was the same as in neonatal vascular SMC.
Little is known about the signaling pathways involved in regulating LOX and its 
relatives. In this study we demonstrate that TNF-a stimulates the MAPK signaling 
pathway, showing increased activation of ERK1/2 and P38 MAPK and very weak 
activation of JNK. However, inhibition of the ERK1/2 pathway only decreases partially 
the up-regulation of LOXL2 and LOXL4 mRNA levels in vascular SMCs suggesting the 
involvement of other pathways in this process. It has been reported that PDGF 
induces LOX expression in SMCs (Smith-Mungo, L.I., et a/., 1998) and this process is 
regulated by the PKC-MEK-MAPK signaling pathway (Smith-Mungo, Lv et a/., 2002). 
In addition, adenosine induces LOX and this process is mediated by cAMP (Ravid, K., 
et a/., 1999) suggesting that several other signaling pathways could be involved in 
LOX isoforms regulation by TNF-a.
From our results we can conclude that TNF-a enhances LOX enzyme activity in SMC 
possibly by increasing both LOXL2 and LOXL4 expression, and this pathway depends 
mostly on pathways other than ERK1/2 activation. Also, the in vivo results from tissues 
on the up-regulation of LOXL4 correspond to effects coming from SMC, whereas the
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activation of the other LOXLs corresponds to other cell types present in the tissue 
samples.
In the second part of this project, we investigated whether LOX-PP could inhibit TNF- 
a proliferation and/or migration of vascular smooth muscle cells and which MAPKs 
mediate these biological responses. It is known that LOX is a tumor suppressor and its 
expression inhibits ras-dependent transformation of fibroblasts (Kenyon, K., et a/., 
1991; Contente, S., et a/., 1990; Hajnal, A., et a/., 1993). Recently, the tumor 
suppressor activity of LOX has been attributed to the pro-peptide region (LOX-PP) 
(Palamakumbura, A.H., et a/., 2004). Other studies had also suggested that LOX-PP 
inhibits tumor formation in breast cancer cells in mice (Min, C., et a/., 2007). LOX is 
highly expressed in atherosclerotic tissues, and in models of balloon angioplasty 
(Brasselet, Cv et a/., 2005; Nuthakki, V.K., et a/., 2004; Kagan, H.M., et a/., 1981). It 
is, therefore, of interest to determine the biological functions of LOX-PP in vascular 
smooth muscle cells.
First, we wanted to determine whether LOX-PP could inhibit proliferation stimulated 
by TNF-a. Unfortunately we could not promote SMC proliferation with any 
concentration of TNF-a detected by DNA synthesis or cell growth assays. FHowever, 
an increase in DNA synthesis was observed when the cells were treated only with
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serum (5-10%). Similar negative effects of TNF-a on SMC proliferation and the 
transient activation of the MAPK signaling pathway have been reported earlier 
(Goetze, S., et a/., 1999). Other studies have suggested that in order to increase SMC 
proliferation, TNF-a needs to be associated with other growth factors such as PDCF 
(Peppel, K., et a/., 2005). However, in our studies, vascular SMCs treated with TNF-a 
combined with various concentrations of serum did not show any increase in 
proliferation. Another reason for this effect could be explained by the presence of 
different subpopulations of SMC that respond differently to TNF-a stimulation. 
According to Wang et a/., with the use of cloning techniques, it was possible to isolate 
two subpopulations of vascular SMCs: spindle- and epithelioid-shaped. TNF-a 
stimulated growth in the spindle SMCs whereas it had a toxic effect on epithelioid 
SMCs, suggesting that TNF-a either promotes growth or induces apoptosis in human 
VSMCs depending on phenotype (Wang, Z., et a/., 2005). Overall, this process is 
controversial. However, our data suggests that LOX-PP inhibits SMC proliferation 
when stimulated with serum instead of TNF-a.
It is reported that TNF-a stimulates migration in SMC via ERK1/2 signaling pathways 
(Goetze, S., et a/., 1999). However, as stated earlier, our data shows that TNF-a 
activates not only ERK1/2 but also P38 and JNK. Using specific inhibitors we observed 
that the TNF-a stimulated migration depends upon ERK1/2, P38 and JNK signaling
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pathways. Our study is the first to report the involvement of all three MAPKs in TNF- 
a stimulated migration of SMC. Interestingly, our data shows that LOX-PP inhibits 
this stimulation almost to the levels of the untreated control cells. This suggests that 
LOX-PP may provide a feedback control mechanism to inhibit the downstream 
effects of activation of MAPKs in SMC.
A future approach to elucidate the involvement of the MAPKs in the processes of 
TNF-a stimulated migration could be the use of a constitutively active mutation of 
ERK, p38 or JNK genes. An experiment could be designed in which ERK, p38 or JNK 
constitutively active mutations are inserted into SMC. Then, transfected SMCs would 
be treated with LOX-PP and migration and proliferation will be measured. By 
comparing the effects on migration and proliferation to untransfected cells we could 
determine which pathway is involved in this process. For example, if a constitutively 
active ERK mutation is inserted in SMC and no changes in the increase in TNF-a 
stimulated migration in response to LOX-PP are detected, we could conclude that the 
ERK signaling pathway is a target of LOX-PP. If a decrease in migration and 
proliferation are detected, this could mean that other signaling pathways are affected 
by LOX-PP.
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Our study revealed that LOX-PP is a weak inhibitor of TNF-a stimulated MMP-9 
synthesis, and that these effects are mediated by inhibition of the ERK1/2 MAPK 
pathway. Deposition of a fibrous extracellular matrix in atherosclerosis was 
considered to be deleterious to disease outcome. Occlusion of the lumen of arteries 
due to excess extracellular matrix accumulation and accretion on lesions was seen to 
be a major factor in restricting blood flow leading to heart damage, but more recent 
findings indicate that thinning of extracellular matrix by MMP-driven proteolysis in 
atherosclerotic lesions leads to thrombolytic events that are more dangerous than 
artery occlusion (Libby, et al., 2005). Proliferation and migration of SMCs also 
contributes to atherosclerotic lesion development. We speculate that increased LOX 
enzyme levels and increased LOX-PP levels in atherosclerosis are potentially of 
benefit to clinical outcomes. Active LOX enzyme contributes to collagen and elastin 
maturation that is required for structural integrity. Our study suggests that LOX-PP is 
an inhibitor of SMC proliferation and migration, serving to limit further SMC 
dependent growth of restenotic and/or atherosclerotic lesions. Therefore, LOX may 
have two different potentially beneficial anti-atherogenic biological activities derived, 
respectively from LOX-PP and LOX enzyme.
From our results we can conclude that LOX-PP is a weak inhibitor of TNF-a 
stimulated MMP-9 synthesis and these effects are mediated by inhibition of the
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ERK1/2 MAPK pathway. Also, LOX-PP is an inhibitor of SMC proliferation and 
migration, serving to limit further SMC dependent growth of restenotic and/or 
atherosclerotic lesions. 1
This is one of the first studies that suggest a possible therapeutic function for the LOX- 
PP to control some of the negative effects of TNF-a in cardiovascular disease. Our 
novel findings stimulate future studies of new in vivo models to further understand 
the biological activities and mechanisms of action of LOX-PP in the context of 
vascular pathologies.
Figure 19 shows the proposed model for this investigation and Figure 20 shows the 
involvement of LOXL4 and LOX-PP in the process of atherosclersis
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Proposed model of the effect of LOX-PP in SMCs biological responses stimulated 
by TNF-a.
Figure 19.
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Proposed model of the effect of LOX-PP in SMCs biological responses stimulated 
by TNF-a.
Figure 19.
The diagram summarizes the proposed model for the effects of the LOX-PP in SMCs.
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Figure 20.
Effect of LOX-PP in the atherosclerosis model
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Effect of LOX-PP in the atherosclerosis model.
As mentioned earlier, atherosclerosis is a complex disease that involves many cell 
types and molecules. The proinflammatory cytokine TNF-a has important effects in 
atherosclerosis. Our results marked in red on the graph show that TNF-a increases 
LOXL4 levels and this effect comes from the SMCs. TNF-a also increases cell 
migration and matrix degradation as shown by the increase of MMP-9 levels. Our 
results also show the LOX-PP inhibits the migration and proliferation of SMCs and 
weakly inhibits the expression of MMP-9. It has been shown that LOX is increased in 
atherosclerotic tissues, therefore LOX-PP levels are also increased. This fact could be 
of potential benefit to inhibit thrombolytic events in atherosclerosis.
Figure 20.
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